

SUPERINDUSTRIA Y COMERCIO
Radicación : 83821717 00000002 Folios: 44 7976
Fecha (GMD): 2003-10-15 16:30:02 2700
Trámite : 000 PATENTES D 1 REGISTRO/ 444 REPUESTA

AS: 90.740

Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

irdycaastro.com.co

Señores

**SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIVISION DE NUEVAS CREACIONES**

E. S. D.

RESPUESTA A OFICIO 08134 DE OCTUBRE 02, 2003

REF: Expediente No. 03 031.717 - Solicitud de Patente a favor de UCB, S.A.
Titulada: **COMPUESTOS QUÍMICOS CON ACTIVIDAD DOBLE,
PROCEDIMIENTOS PARA SU PREPARACIÓN Y COMPOSICIONES
FAMACEUTICAS**

RAMIRO CASTRO DUQUE, vecino de Bogotá, portador de la tarjeta profesional No. 1003, obrando como apoderado de la sociedad UCB, S.A., según lo acredita el documento de poder protocolizado bajo el No. 17161, para dar cumplimiento al requerimiento notificado por fijación en lista el 02 de Octubre de 2003, y de acuerdo con los Artículos 38 y 39 de la Decisión 486 de la comisión de la Comunidad Andina, me permito anexar al presente escrito los siguientes documentos:

1. Documento donde consta la cesión del derecho a la Patente otorgado por los inventores al solicitante, debidamente apostillado.
2. Copia certificada por la Oficina Europea de Patentes de la primera solicitud presentada para la misma Invención, de la cual REIVINDICAMOS PRIORIDAD, junto con su correspondiente traducción del inglés al castellano.
3. Extracto para publicación y Tarjeta de Archivo Temático.

De la señora Jefe atentamente,



RAMIRO CASTRO DUQUE
C.C. No. 170.322 de Bogotá
Código 340
Cra. 7 No. 16-56 Piso 9

Bogotá, Octubre 10, 2003
CHP/MEV/hsr.

92740
AA-10
104

17.43.CO

DOCUMENT OF ASSIGNMENT OF
PATENT

ASSIGNMENT

The undersigned

- 1) Provins Laurent
- 2) Van Keulen Berend Jan
- 3) Surtees John
- 4) Talaga Patrice
- 5) Christophe Bernard

acting as inventors

of "Chemical Compounds with Dual Activity, processes for their
preparation and pharmaceutical compositions"

with domicile in

- 1) Cloe des Platanes 6, B-7060 Solignies (Belgium)
- 2) Avenue Gabrielle Petit 54 R2, B-1480 Tubize (Belgium)
- 3) Kalzerlaan 7, B-3090 Jezus-Eik (Overijse) (Belgium)
- 4) Avenue E. Van Becelaere 24 A/18, B-1170 Watermaal-Bolstfort (BE)
- 5) rue d'Albroux 10, B-1387 Ramillies (Belgium)

hereby declares that it assigns all rights of ownership as well as
all rights and privilege relating thereto without exception over
the following Patent in Colombia:

Title: "Chemical Compounds with Dual Activity, processes for their preparation and
pharmaceutical compositions"

to UCB, S.A.

domiciled in

Allée de la Recherche 60
B-1070 Bruxelles (Belgium)

The assignor and the assignee sign this document as proof of
their acceptance of the assignment.

Given and signed on the 28th day
of February 2003

DOCUMENTO DE TRASPASO DE
PATENTE

CESION

El suscrito

en calidad de

de

con domicilio en

declara por el presente documento que cede todos los derechos
de propiedad que le correspondan, así como las prerrogativas,
sin excepción alguna, sobre la siguiente Patente en Colombia:

a

domiciliada en

El cedente y el cesionario firman este documento como prueba
de su aceptación de la cesión.

Dado y firmado a los días del mes
de de

Signature of Assignor

Firma del cedente

Provins Laurent

Van Keulen Berend Jan

Surtees John

Talaga Patrice

Christophe Bernard

Signature of Assignee

Firma del cesionario

Henriette Van Caenegem
Proxy and Legal Representative

I, Damien Hissette.....
 associate notary, member of the association
 VAN HALTEREN, HISETTE & DERYNCK,
 at 1000 Brussels, rue de l'Association 30,
 do hereby certify that the signature set on
 this document is/are stated to be the signature(s)
 of Dr. Jozef Ruyss, Dr. Patricia van Keulen
Dr. John Swillen, Dr. Patrick Telford, Dr. Christophe Bernad and Hissette van Keulen
 Brussels, March 1st..... 2003

(Handwritten signature)

Damien HISETTE
 Notaire associé - Geassocieerde notaris
 Rue de l'Association 30 Verenigingstraat
 Bruxelles 1000 Brussel

APOSTILLE	
(Convention de La Haye du 6 octobre 1961)	
1. Pays : Belgique	
Le présent acte public	
2. a été signé par	<i>Hissette</i>
3. agissant en qualité de	<i>Notaire</i>
4. est revêtu du sceau / timbre de	<i>Bruxelles</i>
Attesté le 1-03-2003	
5. à Bruxelles	6. le
7. par le Service public fédéral Affaires étrangères, Commerce extérieur et Coopération au Développement	
8. sous le n°	<i>360</i>
9. sceau / timbre :	10. Signature :
	<i>(Handwritten signature)</i>

1
105

TRADUCCIÓN SIMPLE DEL IN LES AL ESPAÑ L de las legalizaciones que se encuentran a continuación de un **DOCUMENT DE TRASPASO DE PATENTE** de parte de 1) Provins Laurent, 2) Van Keulen Berend Jan, 3) Surtees John, 4) Talaga Patrice, 5) Christophe Bernard en su calidad de inventores de "Compuestos químicos con actividad Dual, procesos para su preparación y composiciones farmacéuticas", domiciliados en 1) Clos des Platanes 6, B-7060 Soignies (Bélgica), 2) Avenue Gabrielle Petit 54 R2, B-1480 Tubize (Bélgica) 3) Keizerlaan 7, B-3090 Jesus-Eik (Overijse) (Bélgica), 4) Avenue E. Van Becelaere 24 A/18, B-1170 Watermael-Boitsfort (BE), 5) rue d'Albroux 10, B-1367 Ramillies (Bélgica) a UCB, S.A. , sociedad domiciliada en Allée de la Recherche 60 B-1070 Bruxelles (Bélgica) Otorgado y firmado el 28 de Febrero del 2003.

Firmas de los Cedentes : Provins Laurent, Van Keulen Berend Jan, Surtees John, Talaga Patrice, Christophe Bernard

Firma del cesionario: Henriette Van Caenegem Apoderado y Representante Legal,
El texto del documento no se traduce por estar en Español

El documento está debidamente sellado y firmado al respaldo así:

EN INGLES : Yo, Damien HISETTE, Notario Asociado, miembro de la asociación **VAN HALTEREN, HISETTE & DERYNCK** domiciliada en Rue de l'Association 30, por medio de la presente certifico que las firmas colocadas en este documento se declaran como las firmas de los Srs. Provins Laurent, Van Keulen Berend Jan, Surtees John, Talaga Patrice, Christophe Bernard, y Henriette Van Caenegem Bruselas 10 de Marzo de 2003

Esta declaración va debidamente firmada y sellada por el Notario Damien HISETTE, domiciliado en Rue de l'Association 30 Verenigingstraat , Bruxelles 1000 Bruselas.

APOSTILLE
(Convention de La Haye du 5 Octobre 1961)

1. País : Bélgica

El presente documento público

2. Ha sido firmado por: Hisette

3. Actuando en calidad de : Notario

4. Lleva el sello/timbre de: Bruselas

Certificado

5. En : Bruselas

6. El : 11-03-2003

107
106
/

7. Por el Servicio Público federal de Asuntos Extranjeros,
Comercio Exterior y Cooperación para el Desarrollo
8. Bajo el No.: 032860
9. Sello Timbre: Servicio Público federal de Asuntos Extranjeros,
Comercio Exterior y Cooperación para el Desarrollo - BÉLGICA

Firma (ilegible)



**Europäisches
Patentamt**

**European
Patent Office**

**Office européen
des brevets**

90.740
107 109
80

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02008706.0

**Der Präsident des Europäischen Patentamts:
Im Auftrag**

For the President of the European Patent Office

**Le Président de l'Office européen des brevets
p.o.**

R C van Dijk



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

HD
X 108

Anmeldung Nr:
Application no.: 02008706.0
Demande no:

Anmeldetag:
Date of filing: 18.04.02
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

UCB S.A.
Allée de la Recherche 60
1070 Bruxelles
BELGIQUE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

Chemical compounds with dual activity, processes for their preparation and
pharmaceutical compositions

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)

Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C07D/

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

**Chemical Compounds with Dual Activity, processes for their preparation and
pharmaceutical compositions**

5 The present invention concerns chemical compounds combining affinity and
antagonism against the human m3 muscarinic receptor with activity as selective
phosphodiesterase IV (PDE IV) inhibitors, processes for preparing them,
pharmaceutical compositions containing them and their use as pharmaceuticals.

10 Chronic obstructive pulmonary disease is characterised by airway
inflammation and impaired expiratory outflow due to chronic bronchitis and/or
emphysema. The primary inflammatory cells associated with COPD are macrophages,
CD8+ T-cells and neutrophils.

15 Parasympathetic cholinergic reflexes are the most potent tonically active
regulators of bronchoconstriction and of submucosal gland exocytosis and secretion in
the airways. Post-junctional m3 receptors mediate cholinergic bronchoconstriction
and glandular secretion in the human airways. Prejunctional m2 autoreceptors
modulate the acetylcholine release whereas m1 receptors located on parasympathetic
ganglia inversely facilitate the parasympathetic nerve activity (Barnes P.J., In: "Lung
20 Biology in Health and Disease: Anticholinergic Agents in the Upper and Lower
Airways", Vol. 134, Spector S.L. (Ed), (1999), 91-57).

The nasal mucosa of the upper airway is also innervated by parasympathetic
nerve fibers, activation of which results in glandular hypersecretion from both goblet
cells and submucosal seromucinous glands. Activation of m1 and m3 receptors
results in secretion from mucous and serous glands. The m3 receptor subtype, also
25 present on blood vessels, may play an additional role in nasal congestion through
promoting vasodilatation.

Thereby, M₃ and M₁ muscarinic receptor antagonists are indicated for the
treatment of diseases associated with airway narrowing or/and mucus hypersecretion
(Morley, J. Parasympatholytics in Asthma. Pulmonary Pharmacology (1994), 7, 159-
30 168).

Anticholinergic bronchodilators, particularly selective muscarinic M₃
antagonists, are currently the preferred choice for management of COPD as they are
more effective and have fewer side effects compared to β_2 -adrenoceptor agonists.
Bronchodilators improve symptoms but do not address the underlying chronic
35 inflammation or the changes in airway structure (Hay D.W.P., Current Opinion in
Chemical Biology (2000), 4, 412-419).

Amongst phosphodiesterases, PDE IV is the predominant sub-type in
inflammatory cells, including mast cells, eosinophils, T lymphocytes, neutrophils and

macrophages. It is also the dominant sub-type in structural cells such as sensory nerves and epithelial cells (Torphy T.J., Am. J. Resp. Crit. Care Med. (1998), 157, 351-370).

Standard treatment with corticosteroids as anti-inflammatory agents has demonstrated limited efficacy (Culpitt S.V., Mazlak W., Loukidis S., Nightingale J.A., Matthews J.L., Barnes P.J., Am. J. Resp. Crit. Care Med. (1998), 160, 1635-9); Keatings V.M., Jatakanon A., Wordsell Y.M., Barnes P.J., Am. J. Resp. Crit. Care Med. (1997), 155, 542-8). Selective PDE IV inhibitors, however, have proved to be very efficient in attenuating the responses of various inflammatory cells through their ability to elevate cyclic AMP levels. They are known to modulate activity, migration and apoptosis of neutrophils by inhibiting the production and release of chemokines, superoxide free radicals, leukotrienes and proteolytic and toxic granular enzymes (Torphy T.J., Am. J. Resp. Crit. Care Med. (1998), 157, 351-370).


It has now been found that a combination of these two therapeutic activities, bronchodilatation with an M₃ muscarinic antagonist and anti-inflammatory activity with a selective PDE IV inhibitor, in a single compound, provides a new and surprisingly effective approach to the treatment of COPD.

The compounds according to this invention are useful for treating respiratory disorders in connection with Chronic Obstructive Pulmonary Disease (COPD).

Preferred compounds have affinity for the human m₃ muscarinic receptor at concentrations ranging from 100 nM to almost 1 nM and incorporate activity as selective phosphodiesterase IV (PDE IV) inhibitors at concentrations ranging from 2.5 µM to almost 50 nM. These compounds also recognize the m₁, m₂, m₄ and m₅ receptors with variable receptor subtype selectivity.

Preferred compounds have been proven to antagonise carbachol-induced contraction of guinea-pig trachea in vitro.

In one aspect, the invention therefore provide compounds having the formula I, or a pharmaceutically acceptable salt thereof,



30

wherein

R¹ is alkyl or cycloalkyl.

R² is cycloalkyl.

R³ is hydrogen, alkyl, halogen, hydroxy, alkoxy or amino.

112
110

or R^2R^3 is an alkylene bridging group.

R^4 is hydrogen or alkyl.

R^5 is cycloalkyl, arylalkyl or heterocycle-alkyl.

5 or NR^4R^5 is a heterocycle, which may be substituted, containing only one heteroatom which is a nitrogen atom or containing two heteroatoms wherein one is a nitrogen atom and the other is a non-oxidized sulfur atom,

with the proviso that when R^2R^3 is an alkylene bridging group, R^1 is a cycloalkyl.

10 The term "alkyl", as used herein, is defined as including saturated, monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof and containing 1-20 carbon atoms, preferably 1-8 carbon atoms for non-cyclic alkyl and 3-8 carbon atoms for cycloalkyl (in these two preferred cases, unless otherwise specified, "lower alkyl").

15 Preferred alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, iso- or tert-butyl, and 2,2,2-trimethylethyl.

The term "cycloalkyl", as used herein, refers to a monovalent group of 3 to 18 carbons derived from a saturated cyclic or polycyclic hydrocarbon such as adamantyl. It may be substituted or unsubstituted. Non-limiting examples are cyclopropyl, 20 cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[3.2.1]cyclooctyl or adamantyl.

When present as bridging groups, alkyl represents straight or branched chains, C1-12-, preferably C1-4-alkylene.

25 Groups where branched derivatives are conventionally qualified by prefixes such as "n", "sec", "iso" and the like (e.g. "n-propyl", "sec-butyl") are in the n-form unless otherwise stated.

The term "halogen", as used herein, includes an atom of Cl, Br, F, I.

The term "hydroxy", as used herein, represents a group of the formula -OH.

The term "amino", as used herein, represents a group of the formula -NH₂.

30 The term "thiol", as used herein, represents a group of the formula -SH.

The term "cyano", as used herein, represents a group of the formula -CN.

The term "nitro", as used herein, represents a group of the formula -NO₂.

35 The term "alkoxy", as used herein, is defined as including -O-R⁶ groups wherein R⁶ represents an alkyl or a cycloalkyl group. Non-limiting examples are methoxy and ethoxy.

The term "arylalkyl", as used herein, represents a group of the formula -R⁷-aryl in which R⁷ is C1-12- straight or branched alkylene. Non-limiting examples are

benzyl, halobenzyl, cyanobenzyl, methoxybenzyl, nitrobenzyl, 2-phenylethyl, diphenylmethyl, (4-methoxyphenyl)diphenylmethyl, indenyl, anthracenylmethyl.

The term "aryl" as used herein, is defined as including an organic radical derived from an aromatic hydrocarbon consisting of 1-3 rings and containing 6-30 carbon atoms by removal of one hydrogen, such as phenyl and naphthyl each optionally substituted by 1 to 5 substituents independently selected from halogen, hydroxy, thiol, amino, nitro, cyano, C1-6-alkoxy, C1-6-alkylthio, C1-6-alkyl, C1-6-haloalkyl. Aryl radicals are preferably monocyclic containing 6-10 carbon atoms. Preferred aryl groups are phenyl and naphthyl each optionally substituted by 1 to 5 substituents independently selected from halogen, nitro, amino, azido, C1-6-alkoxy, C1-6-alkylthio, C1-6-alkyl and C1-6-haloalkyl.

The term "alkylthio", as used herein, is defined as including -S-R⁶ groups wherein R⁶ represents an alkyl or a cycloalkyl group. Non-limiting examples are methylthio, ethylthio, propylthio and butylthio.

The term "heterocycle", as used herein is defined as including an aromatic or non aromatic cyclic alkyl, alkenyl, or alkynyl moiety as defined above, having at least one O, S and/or N atom interrupting the carbocyclic ring structure and optionally, one of the carbon of the carbocyclic ring structure may be replaced by a carbonyl. Non-limiting examples of aromatic heterocycles are pyridyl, furyl, pyrrolyl, thienyl, isothiazolyl, imidazolyl, benzimidazolyl, tetrazolyl, quinoxalyl, quinoxalinyl, naphthyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolyl, isoquinolyl, isobenzofuranyl, benzothienyl, pyrazolyl, indolyl, indolizinyl, purinyl, isoindolyl, carbazolyl, thiazolyl, 1,2,4-thiadiazolyl, thieno(2,3-b)furanyl, furopyranyl, benzofuranyl, benzoxepinyl, isooxazolyl, oxazolyl, thianthrenyl, benzothiazolyl, or benzoxazolyl, cinnolinyl, phthalazinyl, quinoxalinyl, phenanthridinyl, acridinyl, perimidinyl, phenanthrolinyl, phenothiazinyl, furazanyl, isochromanyl, indolinyl, xanthenyl, hypoxanthinyl, pteridinyl, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, and pyrazolopyrimidinyl optionally substituted by alkyl or as described above for the alkyl groups. Non-limiting examples of non aromatic heterocycles are tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperidyl, piperazinyl, imidazolidinyl, morpholine, morpholinyl, 1-oxaspiro(4.5)dec-2-yl, pyrrolidinyl, 2-oxo-pyrrolidinyl, 8-thia bicyclo[3.2.1]cyclooctanyl, 1,4-dithiepanyl, tetrahydro-2H-thiopyranyl, azepanyl, azocanyl, or the same which can optionally be substituted with any suitable group, including but not limited to one or more moieties selected from lower alkyl, or other groups as described above for the alkyl groups. The term "heterocycle" also includes bicyclic, tricyclic and tetracyclic, spiro groups in which any of the above heterocyclic rings is fused to one or two rings independently selected from an aryl ring, a cyclohexane ring, a cyclohexene ring, a cyclopentane ring, a cyclopentene ring or another monocyclic heterocyclic ring or where a monocyclic

+211+3

heterocyclic group is bridged by an alkylene group, such as quinuclidinyl, 7-azabicyclo(2.2.1)heptanyl, 7-oxabicyclo(2.2.1)heptanyl, 8-azabicyclo(3.2.1)octanyl.

The term "heterocycle-alkyl", as used herein, represents a group of the formula -R⁷-heterocycle in which R⁷ is C1-12- straight or branched alkylene. Non-limiting examples are thiophenemethyl, thiophenethyl, pyridylmethyl and pyridylethyl.

The term "pharmaceutically acceptable salt" according to the invention includes therapeutically active, non-toxic base and acid salt forms which the compounds of formula I are able to form.

The acid addition salt form of a compound of formula I that occurs in its free form as a base can be obtained by treating the free base with an appropriate acid such as an inorganic acid, for example, a hydrohalic such as hydrochloric or hydrobromic, sulfuric, nitric, phosphoric and the like; or an organic acid, such as, for example, acetic, hydroxyacetic, propanoic, lactic, pyruvic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pantoic and the like.

The compounds of formula I containing acidic protons may be converted into their therapeutically active, non-toxic base addition salt forms, e.g. metal or amine salts, by treatment with appropriate organic and inorganic bases. Appropriate base salt forms include, for example, ammonium salts, alkali and earth alkaline metal salts, e.g. lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.

Conversely said salt forms can be converted into the free forms by treatment with an appropriate base or acid.

Compounds of the formula I and their salts can be in the form of a solvate, which is included within the scope of the present invention. Such solvates include for example hydrates, alcoholates and the like.

Some of the compounds of formula I and some of their intermediates have at least one stereogenic center in their structure. This stereogenic center may be present in a R or a S configuration, said R and S notation is used in correspondance with the rules described in Pure Appl. Chem. 45 (1976) 11-30.


The invention also relates to all stereoisomeric forms such as enantiomeric and diastereomeric forms of the compounds of formula I or mixtures thereof (including all possible mixtures of stereoisomers). Reference to a compound or compounds is intended to encompass that compound in each of its possible isomeric forms and mixtures thereof unless the particular isomeric form is referred to specifically.

Some of the compounds of formula I may also exist in tautomeric forms. Such forms although not explicitly indicated in the above formula, are intended to be included within the scope of the present invention.

The invention also includes within its scope pro-drug forms of the compounds of formula I and its various sub-scopes and sub-groups.

The term "prodrug" as used herein includes compound forms which are rapidly transformed in vivo to the parent compound according to the invention, for example, by hydrolysis in blood. Prodrugs are compounds bearing groups which are removed by biotransformation prior to exhibiting their pharmacological action. Such groups include moieties which are readily cleaved in vivo from the compound bearing it, which compound after cleavage remains or becomes pharmacologically active. Metabolically cleavable groups form a class of groups well known to practitioners of the art. They include, but are not limited to such groups as alkanoyl (i.e. acetyl, propionyl, butyryl, and the like), unsubstituted and substituted carbocyclic aroyl (such as benzoyl, substituted benzoyl, and 1- and 2-naphthoyl), alkoxycarbonyl (such as ethoxycarbonyl), trialkylsilyl (such as trimethyl- and triethylsilyl), monoesters formed with dicarboxylic acids (such as succinyl), phosphate, sulfate, sulfonate, sulfonyl, sulfinyl and the like. The compounds bearing the metabolically cleavable groups have the advantage that they may exhibit improved bioavailability as a result of enhanced solubility and/or rate of absorption conferred upon the parent compound by virtue of the presence of the metabolically cleavable group. T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery System", Vol. 14 of the A.C.S. Symposium Series; "Bioreversible Carriers in Drug Design", ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.

Preferred compounds according to the invention are compounds of formula I



or a pharmaceutically acceptable salt thereof wherein

R¹ is alkyl or C3-7-cycloalkyl,

R² is C3-7-cycloalkyl,

R³ is hydrogen, C1-4-alkyl, halogen, hydroxy, alkoxy or amino,
or R²R³ is a C2-4 alkylene bridging group,

R⁴ is hydrogen or alkyl,

7/11/2

R^5 is C3-7-cycloalkyl, arylalkyl or heterocycle-alkyl.

or NR^4R^5 is a heterocycle, which may be substituted, containing only one heteroatom which is a nitrogen atom or containing two heteroatoms wherein one is a nitrogen atom and the other is a non-oxidized sulfur atom.

5 with the proviso that when R^2R^3 is an alkylene bridging group, R^1 is a cycloalkyl.

Combinations of one or more of these preferred compound groups are especially preferred.

10 Preferably, R^1 is C3-4 alkyl or C3-4 cycloalkyl, more preferably R^1 is selected from the group of cyclopropyl, isopropyl, cyclobutyl, cyclopentyl, 2-methyl-cyclopropyl and cyclopropylmethyl.

15 Preferably, R^2 is C3-4 cycloalkyl, more preferably R^2 is selected from cyclopropyl or cyclobutyl.

20 Preferably, R^3 is hydrogen, methyl, ethyl, a Cl atom, a F atom, a Br atom, amino or methoxy.

In preferred embodiments R^2R^3 is an alkylene bridging group selected from ethylene, propylene and butylene.

25 Preferably, R^4 is hydrogen or C1-4 alkyl, more preferably R^4 is hydrogen or methyl.

30 Preferably, R^5 is 2-(2-thienyl)ethyl, 2-furylmethyl, 2-thienylmethyl, 4-pyridinylmethyl, benzyl, 2-(methylsulfonyl)benzyl, 2,6-difluorobenzyl, 2-fluorobenzyl, 2-nitrobenzyl, 3,5-bis(trifluoromethyl)benzyl, 3,5-difluorobenzyl, cyclohexyl, cycloheptyl, 4-methylcyclohexyl, or 2,2-diphenylethyl.

35 In other preferred embodiments, NR^4R^5 is 1,3-thiazolidin-3-yl, 1-azepanyl, 1-azocanyl, 3,5-dimethyl-1-piperidinyl, 4-(2-methoxyphenyl)-1-piperidinyl, 4-(hydroxy(diphenyl)methyl)-1-piperidinyl, 4-(trifluoromethyl)-1-piperidinyl, 4,4-difluoro-1-piperidinyl, 4,4-dimethyl-1-piperidinyl, 4-amido-1-piperidinyl, 4-benzyl-1-piperidinyl, 4-carboxy-1-piperidinyl, 4-cyano-4-phenyl-1-piperidinyl, 4-ethoxycarbonyl-1-piperidinyl, 4-ethyl-1-piperidinyl, 4-ethyl-4-methyl-1-piperidinyl, 4-

hydroxy-1-piperidinyl, 4-hydroxy-4-phenyl-1-piperidinyl, 4-hydroxymethyl-1-piperidinyl, 4-methyl-1-piperidinyl, 4-methylene-1-piperidinyl, 4-one-1-piperidinyl, 3,6-dihydro-1(2H)-pyridinyl, 3-azabicyclo[3.2.1]oct-3-yl, 4-pyridinylmethyl, 4-thiomorpholinyl, 2-one-1-azepanyl, 3,4-dihydro-2(1H)-isoquinolinyl, 1,4-dioxo-8-azaspiro[4.5]dec-8-yl, 1,3,3-trimethyl-5-azabicyclo[3.2.1]oct-6-yl, octahydro-2(1H)-isoquinolinyl or 8-azaspiro[4.5]dec-8-yl.

Most preferred compounds are:


6-[1-azepanyl]-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine; N-[6-(1-azepanyl)-5-chloro-2-cyclopropyl-4-pyrimidinyl]-N-cyclopropylamine; 6-azepan-1-yl-5-bromo-N,2-dicyclopropylpyrimidin-4-amine; 6-(1-azepanyl)-N,2-dicyclopropyl-4-pyrimidinamine; 6-(1-azepanyl)-N⁴,2-dicyclopropyl-4,5-pyrimidinediamine; 6-azepan-1-yl-N-cyclopropyl-2-isopropyl-5-methylpyrimidin-4-amine; 6-(1-azepanyl)-N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-4-pyrimidinamine; 6-(1-azocanyl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-[4-(trifluoromethyl)piperidin-1-yl]pyrimidin-4-amine; N,2-dicyclopropyl-6-(4,4-difluoro-1-piperidinyl)-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-6-(4,4-dimethyl-1-piperidinyl)-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-6-(4-ethyl-1-piperidinyl)-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-5-ethyl-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine; N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-(4-methylene-1-piperidinyl)-4-pyrimidinamine; N,2-dicyclopropyl-6-(3,6-dihydro-1(2H)-pyridinyl)-5-methyl-4-pyrimidinamine; 6-(3-azabicyclo[3.2.1]oct-3-yl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-5-ethyl-6-(4-thiomorpholinyl)-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-(4-thiomorpholinyl)-4-pyrimidinamine; N⁴,2-dicyclopropyl-N⁶-(2,6-difluorobenzyl)-5-methyl-4,6-pyrimidinediamine; N⁴-cyclohexyl-N⁶-cyclopropyl-2-(2-methylcyclopropyl)pyrimidine-4,6-diamine; N⁴,2-dicyclopropyl-5-methyl-N⁶-(4-methylcyclohexyl)-4,6-pyrimidinediamine; 6-(1-azepanyl)-N-cyclopentyl-2-cyclopropyl-5-methyl-4-pyrimidinamine; 4-azepan-1-yl-2-cyclopropyl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidine and 4-azepan-1-yl-2-cyclopropyl-6,7,8,9-tetrahydro-pyrimido[4,5-b]azepine, or pharmaceutically acceptable salts thereof.

The present invention concerns also processes for preparing the compounds of formula I.

The following process description sets forth certain synthesis processes in an illustrative manner. Other alternative and/or analogous methods will be readily apparent to those skilled in this art.

113


A. According to one embodiment, compounds having the general formula I wherein $R^3 = H$, alkyl, halogen, alkoxy or hydroxy may be prepared by reaction of a compound of formula II wherein $R^3 = H$, alkyl, halogen, alkoxy or hydroxy with an amine of formula III according to the equation:



This reaction may be carried out without solvent in the case of high-boiling point amines of formula III or in a high-boiling point alcohol (e.g.: 1-methoxy-2-propanol) as solvent in the case of solid or low boiling point amines of formula III, between 80 and 130 °C.

Compounds of formula III are commercially available or may be prepared under any conventional methods known to the person skilled in the art.

Compounds of formula II wherein $R^3 = H$, alkyl, halogen, alkoxy or hydroxy may be prepared by reaction of a compound of formula IV wherein $R^3 = H$, alkyl, halogen, alkoxy or hydroxy with a primary amine of formula V according to the equation:




This reaction may be carried out without solvent or in dichloromethane as a solvent, between 30 and 80 °C.

Compounds of formula V are commercially available.

10

Compounds of formula IV wherein $R^3 = H$, alkyl, halogen, alkoxy or hydroxy may be prepared by reaction of a compound of formula VI wherein $R^3 = H$, alkyl, halogen, alkoxy or hydroxy with phosphorus oxychloride according to the equation:




5

This reaction may be carried out in boiling phosphorus oxychloride in the presence of one equivalent of N,N-diethylaniline as described in: Evans R.F., Savage G.P., Gough D.A., Aust. J. Chem. (1960), 43, 733-740 or in: Biagi G., Giorgi I., Livi O., Scartoni V., Lucacchini A., Farmaco (1997), 52, 51-66.

10

Compounds of formula VI wherein $R^3 = H$, alkyl, halogen, alkoxy or hydroxy may be prepared by reaction of a compound of formula VII with a dialkylmalonate of formula VIII wherein $R^3 = H$, alkyl, halogen, alkoxy or hydroxy and $R^8 = C1-4\text{-alkyl}$ according to the equation:

15




20

This reaction may be carried out in an alcoholic solvent, for example methanol or ethanol, in the presence of 2 equivalents of metallic sodium as a base between 60 and 80 °C as described in: Gershon H., Braun R., Scala A., Rodin R., J. Med. Chem. (1964), 7, 808.

Compounds of formula VIII are commercially available.


25

Compounds of formula VII are commercially available or may be prepared from the corresponding nitrile IX according to the equation:



This reaction may be carried out as described in: Moss R.A., Liu W., Krogh-Jespersen K., Tetrahedron Lett. (1993), 34, 6025-6028.


- B. According to another embodiment, compounds having the general formula I wherein $R^3 = NH_2$ may be prepared by reduction of the corresponding compound of formula I-A according to the equation:



- This reaction may be carried out by any conventional method known to the person skilled in the art, for example aqueous sodium dithionite in dioxane in the presence of ammonia as described in: Chorvat R.J. et al., J. Med. Chem. (1999), 42, 833-848.


- Compounds of formula I-A wherein $R^3 = NO_2$ may be prepared from a compound VI wherein $R^3 = NO_2$ following the procedure described in A.

- Compounds of formula VI wherein $R^3 = NO_2$ may be prepared by reaction of the corresponding compound of formula VI wherein $R^3 = H$ with nitric acid according to the equation:




- This reaction may be carried out using fuming nitric acid in glacial acetic acid between 30 and 40 °C as described in: Beck J.P. et al., Bioorg. Med. Chem. Lett. (1999), 9, 967 or in: Bagli J. et al., J. Med. Chem. (1988), 31, 814.

C. According to another embodiment, compounds having the general formula I wherein $R^3 = \text{Br}$ may be prepared by bromination using N-bromosuccinimide (NBS) of a compound of formula I wherein $R^3 = \text{H}$ according to the equation:




This reaction may be carried out in chloroform as described in: Chen C., Dagnino R., De Souza E.B., Grigoriadis, D.E., Huang C.Q., J. Med. Chem. (1996) 39, 4358-4360.

D. According to another embodiment, compounds having the general formula I wherein R^2R^3 is an alkylene bridging group of formula $-(\text{CH}_2)_n-\text{CH}_2-$, with $n = 1-6$ may be prepared by reaction of a compound of formula X wherein $n = 1-6$ with an amine of formula III according to the equation:




This reaction may be carried out without solvent in the case of high-boiling point amines of formula III or in a high-boiling point alcohol (e.g.: 1-methoxy-2-propanol) as solvent in the case of solid or low boiling point amines of formula III, between 80 and 130 °C.

D.1 Compounds of formula X wherein $n = 2-6$ may be prepared by heating a compound of formula IV wherein R^3 represents $-\text{CH}_2-(\text{CH}_2)_n-\text{NH}_2$ with $n = 2-6$ according to the equation:



This reaction may be carried out in a high-boiling point alcohol (e.g.: 1-methoxy-2-propanol) as solvent, between 120 and 140 °C.


Compounds of formula IV wherein R^3 represents $-\text{CH}_2-(\text{CH}_2)_n-\text{NH}_2$, with $n = 2-6$, may be prepared by reaction of a compound of formula VI wherein R^3 represents $\text{CH}_2-(\text{CH}_2)_n-\text{NHBoc}$, with $n = 2-6$, with phosphorus oxychloride according to the equation:



This reaction may be carried out in boiling phosphorus oxychloride in the presence of 1 equivalent of N,N-diethylamine as described in Evans R.F., Savage G.P., Gough D.A., Aust. J. Chem. (1980), 43, 733-740 or in: Biagi G., Giorgi L., Livi O., Lucacchini A., Farmaco (1997), 52, 61-66.

Compounds of formula VI wherein R^3 represents $-\text{CH}_2-(\text{CH}_2)_n-\text{NHBoc}$, with $n = 2-6$, may be prepared by reaction of a compound of formula VII with a dialkylmalonate of formula VIII wherein R^3 represents $-\text{CH}_2-(\text{CH}_2)_n-\text{NHBoc}$, with $n = 2-6$, according to the procedure described in A.

Compounds of formula VIII wherein R^3 represents $-\text{CH}_2-(\text{CH}_2)_n-\text{NHBoc}$, with $n = 2-6$, may be prepared by reaction the corresponding compound of formula VIII wherein $R^3 = \text{H}$ with a compound of formula XI wherein L is a leaving group according to the equation:




This reaction may be carried out starting from protected alkyl amines bearing a leaving group L (e.g.: halogen, mesylate) in an alcoholic solvent, for example

methanol or ethanol, in the presence of 2 equivalents of metallic sodium as a base between 60 and 80 °C.

Compounds of formula VIII are commercially available.


Compounds of formula XI may be prepared by any conventional methods known to the person skilled in the art.

D.2 Compounds of formula X wherein $n = 1$ may be prepared by reaction of a compound of formula XII with phosphorus oxychloride according to the equation:



This reaction may be carried out in boiling phosphorus oxychloride.

Compounds of formula XII may be prepared by reaction of a compound of formula VII with 2-ethoxy-4,5-dihydro-3H-pyrrole-3-carboxylic acid ethyl ester (XIII) according to the equation:



This reaction may be carried out in an alcoholic solvent, for example methanol or ethanol, in the presence of 1 equivalent of metallic sodium as a base between 60 and 80 °C as described in: Garshon H., Braun R., Scala A., Rodin R., J. Med. Chem. (1964), 7, 808 and in: Granik V.G., Glushkov R.G., Pharm. Chem. J. [Engl. Transl.] (1967), 5, 247-249.


2-Ethoxy-4,5-dihydro-3H-pyrrole-3-carboxylic acid ethyl ester of formula (XIII) may be prepared as described in: Granik V.G., Glushkov R.G., Pharm. Chem. J. [Engl. Transl.] (1967), 5, 247-249 and in: Lindstrom K.J., Crooks S.L., Synth. Commun. (1990), 2335-2337.

When compounds of formula I present one or several stereogenic centres, and that non-stereoselective methods of synthesis are used, resolution of the mixture of

116

stereoisomers can best be effected in one or several steps, involving generally sequential separation of mixtures of diastereomers into their constituting racemates, using preferably chromatographic separations on achiral or chiral phase in reversed or preferably in direct mode, followed by at least one ultimate step of resolution of each racemate into its enantiomers, using most preferably chromatographic separation on chiral phase in reversed or preferably in direct mode. Alternatively, when partly stereoselective methods of synthesis are used, the ultimate step may be a separation of diastereomers using preferably chromatographic separations on achiral or chiral phase in reversed or preferably in direct mode.

In another embodiment, the present invention concerns also the synthesis intermediates of formula II




wherein R^1 and R^2 are as defined above and R^3 is hydrogen, alkyl, halogen, alkoxy or hydroxy.

Preferably, the synthesis intermediates of formula II are selected from the group consisting of 6-chloro-N,2-dicyclopropyl-5-fluoro-4-pyrimidinamine, 6-chloro-N,2-dicyclopropyl-4-pyrimidinamine, 6-chloro-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine, 5,6-dichloro-N,2-dicyclopropyl-4-pyrimidinamine, 6-chloro-N,2-dicyclopropyl-5-methoxy-4-pyrimidinamine, 6-chloro-N,2-dicyclopropyl-5-ethyl-4-pyrimidinamine, N-[6-chloro-2-(2-trans-methylcyclopropyl)-4-pyrimidinyl]-N-cyclopropylamine and its enantiomers, 6-chloro-N-cyclopropyl-5-methyl-2-(2-trans-methylcyclopropyl)-4-pyrimidinamine, 6-chloro-N-cyclopropyl-5-methyl-2-(2-cis-methylcyclopropyl)-4-pyrimidinamine, N-[6-chloro-2-(cyclopropylmethyl)-5-methyl-4-pyrimidinyl]-N-cyclopropylamine, 6-chloro-2-cyclobutyl-N-cyclopropyl-5-methyl-4-pyrimidinamine, 6-chloro-N,2-dicyclopropyl-5-nitro-4-pyrimidinamine, 6-chloro-N-cyclobutyl-2-cyclopropyl-5-methyl-4-pyrimidinamine, 6-chloro-N-cyclopropyl-2-isopropyl-5-methyl-4-pyrimidinamine and 6-chloro-2-cyclopentyl-N-cyclopropyl-5-methyl-4-pyrimidinamine.

In another embodiment, the present invention concerns the following synthesis intermediate of formula VII: 2-methylcyclopropanecarboximidamide.

In another embodiment, the present invention concerns the synthesis intermediates of formula VI



5 wherein R^1 is as defined above and R^3 is alkoxy

Preferably, the synthesis intermediates of formula VI are selected from the group consisting of: 2-cyclopropyl-5-fluoro-4,6-pyrimidinediol, 5-chloro-2-cyclopropyl-4,6-pyrimidinediol, 2-cyclopropyl-5-methoxy-4,6-pyrimidinediol, 2-cyclopropyl-5-ethyl-4,6-pyrimidinediol, 2-(2-methylcyclopropyl)-4,6-pyrimidinediol, 5-methyl-2-(2-methylcyclopropyl)-4,6-pyrimidinediol, 2-(cyclopropylmethyl)-5-methyl-4,6-pyrimidinediol, 2-cyclobutyl-5-methyl-4,6-pyrimidinediol, 2-cyclopentyl-5-methyl-4,6-pyrimidinediol, [3-(2-cyclopropyl-4,6-dihydroxy-pyrimidin-5-yl)-propyl]-carbamate acid tert-butyl ester, [4-(2-cyclopropyl-4,6-dihydroxy-pyrimidin-5-yl)-butyl]-carbamate acid tert-butyl ester.


10
15

In another embodiment, the present invention concerns the following synthesis intermediates of formula IV: 4,6-dichloro-2-cyclopropyl-5-fluoropyrimidine, 4,5,6-trichloro-2-cyclopropylpyrimidine, 4,6-dichloro-2-cyclopropyl-5-pyrimidinyl methyl ether, 4,6-dichloro-2-cyclopropyl-5-ethylpyrimidine, 4,6-dichloro-2-(2-methylcyclopropyl)pyrimidine, 4,6-dichloro-5-methyl-2-(2-methylcyclopropyl)pyrimidine, 4,6-dichloro-2-(cyclopropylmethyl)-5-methylpyrimidine, 4,6-dichloro-2-cyclobutyl-5-methylpyrimidine, 4,6-dichloro-2-isopropyl-5-methylpyrimidine, 4,6-dichloro-2-cyclopentyl-5-methylpyrimidine.

20
25

In another embodiment, the present invention concerns the following synthesis intermediate of formula I-A: 6-(1-azepanyl)-N,2-dicyclopropyl-5-nitro-4-pyrimidinamine.


30 In another embodiment, the present invention concerns the synthesis intermediates of formula X



wherein n is 1-6 and R^1 is as defined above.

Preferably, the synthesis intermediates of formula X are selected from the group consisting of: 4-chloro-2-cyclopropyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine, 4-chloro-2-cyclopropyl-5,6,7,8-tetrahydro-5H-pyrido[2,3-d]pyrimidine, and 4-chloro-2-cyclopropyl-6,7,8,9-tetrahydro-5H-pyrimido [4,5-b] azepine.

In another embodiment, the present invention concerns the synthesis intermediates of formula XII



(XII)

wherein R^1 is cycloalkyl.

Preferably, the synthesis intermediate of formula XII is 2-cyclopropyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-ol.

It has now been found that compounds of formula I and their pharmaceutically acceptable salts are useful in a variety of pharmaceutical indications.

For example, the compounds according to the invention are useful for the treatment of respiratory disorders in connection with the Chronic Obstructive Pulmonary Disease (COPD).

These compounds may also be used for treating symptoms related to disorders such as chronic bronchitis, emphysema, cough, either directly linked to COPD or not, and also cystic fibrosis, pulmonary fibrosis, adult respiratory distress syndrome, rhinitis and asthma.

Preferred compounds have antagonist activity against the human m3 muscarinic receptor at concentrations ranging from 100 nM to almost 1 nM and incorporate activity as selective phosphodiesterase IV (PDE IV) inhibitors at concentrations ranging from 2.5 μ M to almost 50 nM. These compounds also recognize the m1, m2, m4 and m5 receptors with variable receptor subtype selectivity.

Preferred compounds have been proven to antagonise carbachol-induced contraction of guinea-pig trachea in vitro.

In addition the compounds according to the invention may be used in the treatment of the following symptoms which are related to PDE IV or M3:

PDE IV-related

Amongst PDEs, PDE IV is highly selective for cAMP. Four human PDE IV subtypes have been identified, with distinct tissue and cellular distribution. PDE IVA appears to be distributed ubiquitously. PDE IVB is expressed in heart, brain, skeletal muscle and lung. PDE IVC is abundant in neuronal tissue but is absent from immune and inflammatory cells. PDE IVD is abundant in immune and inflammatory cells. Functional effects such as those associated with gastric acid secretion, relaxation of the myometrium, bronchorelaxation and diuresis in the kidney have been attributed to the effect of PDE IV inhibition. This argues in favour of the interest of such approach for treating GI disorders, kidney dysfunction, respiratory and inflammatory disorders.

Furthermore, PDE IV may also be of biological significance and therapeutic relevance in CNS therapeutic indications such as depression and dementia. The hypothesis is that enhanced cAMP availability produced by inhibition of PDE IV stimulates the increase in noradrenaline function produced by classical antidepressants such as imipramine at the post-synaptic level (Wachtel H., Pharmacopsychiatry (1990), 23, 27-32). Denbufylline has also been shown to increase cAMP in cortical slices, indicating a potential in the treatment of cognitive impairment (Nicholson C.D., Psychopharmacology (1990), 101, 147-159).

In addition, the PDE IV enzyme may also be a potential target for anticancer therapy, due to its inhibitory effect on tumour cell growth (Drees M., Zimmermann R., Eisenbrand G., Cancer Res. (1993), 53, 3058-3061), and PDE IV inhibition may be beneficial in tissue transplantation (Plosky D., Oz M., Morris S., J. Clin. Invest. (1993), 92, 2994-3002) and for cardiovascular diseases including atherosclerosis and hypertension (Demouliou-Mason C., Exp. Opin. Ther. Patents (1994), 4, 813-823).

M₃-related**Lower urinary tract disorders:**

The parasympathetic nervous system is the principal excitatory innervation to the detrusor smooth muscle of the urinary bladder. Acetylcholine, released from postganglionic cholinergic nerves, activates post-junctional muscarinic receptors in the detrusor which causes contraction of the bladder that is coordinated with outlet relaxation and leads to voiding of urine (De Groat W.C., Booth A.M., Yoshimura N., In: "Nervous control of the urogenital system", Maggi C.A. (Ed). Harwood Academic Publishers, Amsterdam, (1993), 227-290). Both m₂ and m₃ muscarinic receptors are expressed in the smooth muscle of the bladder detrusor (Hegde S.S., Eglen R.M., Life Science (1999), 64, 419-428). Muscarinic m₃ receptors play a key role in mediating the contractile effect of Acetylcholine (ACh) but m₂ receptors may also contribute to

micturition through opposing the relaxing effect of adrenergic sympathetic tone. Prejunctional m1 facilitory muscarinic receptors may also be involved.

Aging, inflammation or irritants and neurological trauma may result in increased nerve afferent and efferent activity and overactive bladder to become a leading cause of trouble presenting some symptoms such as urgency and frequency micturition and incontinence.

Therefore, non-selective muscarinic M3 antagonists have utility in the treatment of bladder disorders including urge and mixed urinary incontinence, pollakiuria, neurogenic or unstable bladder, hyperreflexia and chronic cystitis (Gillberg P.G., Sundquist S., Nilvebrant L., Eur. J. Pharmacol. (1998), 349, 285-292; Schwantes U., Topfmeler P., International Journal of Clinical Pharmacology and Therapeutics (1999), 37, 209-218; Andersson K.E. et al., In: "Incontinence. 1st International Consultation on Incontinence- June 28 - July 1, 1998 - Monaco", Abrams P., Khouri S., Wein A., Les Editions Vingt et Un, Paris, (1999), 447-486).

Gastrointestinal disorders:

Contractility of the smooth muscle of the gastrointestinal tract is under the control of parasympathetic tone and Acetylcholine (ACh). Contraction of the intestinal smooth muscle is principally dependent upon activation of muscarinic m3 receptors although stimulation of m2 muscarinic receptors might synergize with m3-mediated responses (Sawyer G.W., Ehlert F.J., J. Pharmacol. Exp. Ther. (1998), 284, 269-277).

Gastric secretion is also under the control of the parasympathetic nervous system. Secretagogue effect of ACh depend on the activation of post-junctional m3 receptors whilst m1 receptors located on the post-ganglionic nerves of the myenteric plexus have a facilitory role on the parasympathetic nerve activity.

Therefore, m3 and m1 muscarinic receptor antagonists are potentially useful for treating gastrointestinal disorders associated with intestinal hypermotility such as irritable bowel syndrome, spastic colitis and diverticulosis (Wallis R.M., Napier C.M., Life Science (1999), 64, 395-401) and to reduce acid secretion, gastric motility, to aid the healing of peptic ulcers and to treat gastroesophageal reflux disease and stress-related erosive syndrome (Rademaker J.W., Hunt R.H., Scand. J. Gastroenterol. (1990), 25, 19-26; Coruzzi G., Adami M., Bertacchini G., Arch. Int. Pharmacodyn. Ther. (1988), 302, 232-241).

CNS - Cognitive disorders

The release of acetylcholine from central cholinergic nerves is under autoinhibitory control via m2 or m4 autoreceptors.

Therefore, M2 or M4 antagonists might reduce the levels of ACh released and may offer a potential approach for the treatment of cognitive disorders causally related

to a deterioration or deficit of cortical cholinergic neurons, such as in senile dementia and Alzheimer's disease (Doods H.N., Guimrion R., Mihm G., Life Science (1993), 52, 497-503).

5 **CNS - Locomotor disorders**

The nigrostriatum has many more m4 receptors than any other tissue (Santiago M.P., Potter L.T., Brain Res. (2001), 894, 12-20). These receptors exert inhibitory control on Dopamine (D1) receptor mediated locomotor stimulation (Gomera J., Zhang L., Kostenis E., Felder C., Bymaster F., Brodtkin J., Shannon H., Xia B., Deng C., Wess J., Proc. Natl. Acad. Sci. USA. (1999), 96, 10483-10488).

Therefore, centrally active M₄ muscarinic antagonists may have the potential to treat Parkinsonian's disorders and dyskinesia thought to be causally related to a deterioration of dopaminergic neurons in the nigrostriatum (Salamone J.D., Carlson B.B., Correa M., Wisniewski A., Nisenbaum E., Nisenbaum L., Felder C., In: "Society for Neuroscience 30th Annual Meeting New Orleans, Nov 2000", Mayorga et al., (1999), Abstract 278.5; Mayorga A.J., Cousins M.S., Trevitt J.T., Conlan A., Gianutsos G., Salamone J.D., Eur. J. Pharmacol. (1999), 364, 7-11).

20 **CNS - feeding disorders**

Activation of muscarinic m3 receptors located in the lateral hypothalamus contributes to feeding behaviour (Yamada M. et al., Nature (2001), 410, 207-212).

Thereby, M₃ antagonists may offer new therapeutic perspectives for the treatment of obesity, bulimia and metabolic syndrome.

25 **CNS - sleeping disorders**

Activation of m1 and m3 receptors in the mediodorsal pontine tegmentum results in a marked increased in paradoxical sleep indicating that centrally active M₃ antagonists can be useful for treating sleep disorders (Imeri L., Bianchi S., Angeli P., Mancini M., Brain Res. (1994), 636, 68-72; Sakai, K., Onoe H., Eur. J. Neurosci. (1997), 9, 415-23).

30 **Cardiovascular disorders**

The heart rate is under parasympathetic tone via muscarinic m2 receptors on the SA node.

35 Therefore, m₂ receptor antagonists are of potential value in the emergency treatment of acute myocardial infarction where the dominant autonomic influence of the heart is via the vagus nerve, causing sinus or nodal bradycardia (Van Zwieten P.A., Doods H.N., Cardiovascular Drugs and Therapy (1995), 9, 159-167).

124
119

Thus the present invention concerns a compound of formula I or a pharmaceutically acceptable salt thereof for use as a medicament.

5 In a further aspect, the present invention concerns the use of a compound of formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of PDE IV and/or Mg related disorders such as mentioned above.

10 In particular, the present invention concerns the use of a compound of formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of COPD or of symptoms related to disorders such as chronic bronchitis, emphysema, cough, cystic fibrosis, pulmonary fibrosis, adult respiratory distress syndrome, rhinitis and asthma.

15 The present invention also concerns a method for treating COPD or symptoms related to disorders such as chronic bronchitis, emphysema, cough, cystic fibrosis, pulmonary fibrosis, adult respiratory distress syndrome, rhinitis and asthma in a mammal in need of such treatment, comprising administering at least one compound of formula I or a pharmaceutically acceptable salt thereof to a patient.

20 The term "treatment" as used herein includes curative treatment and prophylactic treatment. By "curative" treatment is meant efficacy in treating a current symptomatic episode of a disorder or condition. By "prophylactic" treatment is meant prevention of the occurrence or recurrence of a disorder or condition.

For treating diseases, compounds of formula I, or their pharmaceutically acceptable salts, may be employed at an effective daily dosage and administered in the form of a pharmaceutical composition.

25 Therefore, another embodiment of the present invention concerns a pharmaceutical composition comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable diluent or carrier.

30 To prepare a pharmaceutical composition according to the invention, one or more of the compounds of formula I or a pharmaceutically acceptable salt thereof, is intimately admixed with a pharmaceutical diluent or carrier according to conventional pharmaceutical techniques known to the skilled practitioner.

35 Pharmaceutical compositions comprising compounds according to the invention can, for example, be administered orally or parenterally, i.e., intravenously, intramuscularly, subcutaneously or by inhalation (orally or intranasally). In a preferred embodiment, the pharmaceutical compositions are administered by inhalation.

Pharmaceutical compositions suitable for oral administration can be solids or liquids and can, for example, be in the form of tablets, pills, dragees, gelatin capsules,

solutions, syrups, aerosols, powders for inhalation and the like. Pharmaceutical compositions suitable for administration by inhalation are preferred.

The following examples are provided for illustrative purposes.

5

1 **EXAMPLE 1: Analytical characterization of the compounds.**

Unless otherwise specified in the examples, characterization of the compounds was performed according to the following methods:

10 NMR spectra are recorded on a BRUKER AC 250 Fourier Transform NMR Spectrometer fitted with an Aspect 3000 computer and a 5 mm $^1\text{H}/^{13}\text{C}$ dual probehead or BRUKER DRX 400 FT NMR fitted with a SG Indigo2 computer and a 5 mm inverse geometry $^1\text{H}/^{13}\text{C}/^{15}\text{N}$ triple probehead. The compound is studied in DMSO- d_6 (or CDCl_3) solution at a probe temperature of 313 K and at concentrations ranging from 2 to 20 mg/ml. The instrument is locked on the deuterium signal of
15 DMSO- d_6 (or CDCl_3). Chemical shifts are given in ppm downfield from TMS taken as internal standard.

Mass spectrometric measurements in LC/MS mode are performed as follows:

HPLC conditions

20 Analyses are performed using a WATERS Alliance HPLC system mounted with an INERTSIL ODS 3-, DP 5 μm , 250 X 4.6 mm column.

The gradient runs from 100 % solvent A (acetonitrile, water, TFA (10/90/0.1, v/v/v)) to 100 % solvent B (acetonitrile, water, TFA (90/10/0.1, v/v/v)) in 7 min with a hold at 100 % B of 4 min. The flow rate is set at 2.5 ml/min and a split of 1/10 is used just before API source. The chromatography is carried out at 30 °C.

25

MS conditions

30 Samples are dissolved in acetonitrile/water, 70/30, v/v at the concentration of about 250 $\mu\text{g}/\text{ml}$. API spectra (+ or -) are performed using a FINNIGAN (San Jose, CA, USA) LCQ ion trap mass spectrometer. APCI source operates at 450 °C and the capillary heater at 160 °C. ESI source operates at 3.5 kV and the capillary heater at 210 °C.

Mass spectrometric measurements in EI/DIP mode are performed as follows: samples are vaporized by heating the probe from 50 °C to 250 °C in 5 min. EI (Electron Impact) spectra are recorded using a FINNIGAN (San Jose, CA, USA) TSQ 700 tandem quadrupole mass spectrometer. The source temperature is set at 150 °C.

35

Specific rotation is recorded on a Perkin-Elmer MC241 or MC341 polarimeter. The angle of rotation is recorded at 25 °C on 1 % solutions in MeOH. For some molecules, the solvent is CH_2Cl_2 or DMSO, due to solubility problems.

2/12/22
120

Water content is determined using a Metrohm microcoulometric Karl Fischer titrator.

Preparative chromatographic separations are performed on silicagel 60 Merck, particle size 15-40 μm , reference 1.15111.9025, using in-house modified Jobin Yvon-type axial compression columns (80 mm i.d.), flow rates between 70 and 150 ml/min. Amount of silicagel and solvent mixtures are as described in individual procedures.


Preparative chiral chromatographic separations are performed on a DAICEL Chiralpak AD 20 μm , 100*500 mm column using an in-house build instrument with various mixtures of lower alcohols and C5 to C8 linear, branched or cyclic alkanes at $\pm$ 350 ml/min. Solvent mixtures are as described in individual procedures.

Melting points are determined on a Büchi 535 or 545 Tottoli-type fusionometre, and are not corrected, or by the onset temperature on a Perkin Elmer DSC 7.

Unless specified otherwise in the examples, the compounds are obtained in the neutral form.


2 EXAMPLE 2: Synthesis of amidines of formula VII.

2.1 Synthesis of 2-methylcyclopropanecarbonitrile 1.



To a suspension of sodium hydride (11 g, 0.28 mol, 60 % in oil, washed two times with n-hexane) in tetrahydrofuran (150 ml) is added diethyl cyanomethylphosphonate (45.5 g, 0.25 mol) over 0.5 h, at room temperature. The mixture is stirred 0.25 h. Propylene oxide (16.3 g, 0.28 mol) is added dropwise at room temperature and the solution is stirred for 1 h then heated at reflux for 4 h. The mixture is cooled and ammonium chloride (115 g) is added. The solvent is distilled, the residue is poured onto crushed ice and extracted three times with diethyl ether. The combined organic layers are washed with brine, dried over magnesium sulfate, concentrated (atmospheric pressure) and the final residue is distilled under reduced pressure (75 °C, 70 mm Hg) to afford pure 2-methylcyclopropanecarbonitrile 1 (7.5 g, 33 %) as an oil.


2.2 Synthesis of 2-methylcyclopropanecarboximidamide hydrochloride 2.



Gaseous hydrochloric acid is passed through a solution of 2-methylcyclopropanecarbonitrile 1 (7.5 g, 82 mmol) in ethanol (8.5 ml) at 0 °C until 7 g have been absorbed. The resulting mixture is kept in the refrigerator for 48 h. Ethanol (150 ml) is then added and gaseous ammonia is passed through the solution at -5 °C for 4 h. The solvent is evaporated in vacuo. Hydrochloric acid in diethyl ether (3 N solution, 3 ml) is added and the solution is concentrated and dried in vacuo to afford 2-methylcyclopropanecarboximidamide hydrochloride 2 (6.15 g, 50 %) as a paste that is used without further purification.

3 EXAMPLE 3: synthesis of 4,6-pyrimidinediol derivatives of formula VI.

3.1 Synthesis of 2-cyclopropyl-5-fluoro-4,6-pyrimidinediol 3.



Sodium (646 mg, 28 mmol) is dissolved in methanol (50 ml) under a nitrogen atmosphere. Cyclopropanecarboximidamide hydrochloride (3.40 g, 28 mmol) is added in one portion. The mixture is stirred at room temperature for 0.25 h, then filtered upon hyflocel. The filtrate is concentrated in vacuo. This free base is added to a solution of sodium (1.29 g, 56 mmol) in methanol (50 ml) under a nitrogen atmosphere, at room temperature. Diethylfluoromalonate (5 g, 28 mmol) is added and the mixture is stirred at 60 °C for 5 h. The solvent is evaporated and the yellowish solid obtained is dissolved in 60 ml of water. The pH is adjusted at 6 with a 5 N HCl solution and the white precipitate formed is filtered and dried. 2-cyclopropyl-5-fluoro-4,6-pyrimidinediol 3 (3.6 g, 76 %) is obtained as a white powder and used in the next step without further purification.

¹H NMR (250 MHz, DMSO): 0.95 (m, 4H), 1.83 (m, 1H), 12.1 (bs, 2H).


Compounds described in table 1 can be synthesized in an analogous way.

2423
121

Table 1

4	2-cyclopropyl-4,6-pyrimidinediol	Patent Geigy 1966, NL6513321
5	2-cyclopropyl-5-methyl-4,6-pyrimidinediol	MS (M ⁺): 166
6	5-chloro-2-cyclopropyl-4,6-pyrimidinediol	MS (M ⁺): 187/189
7	2-cyclopropyl-5-methoxy-4,6-pyrimidinediol	MS (M ⁺): 182
8	2-cyclopropyl-5-ethyl-4,6-pyrimidinediol	MS (M ⁺): 180
9	2-(2-methylcyclopropyl)-4,6-pyrimidinediol	¹ H NMR (250 MHz, DMSO): 0.83 (m, 1H), 1.11 (d, 3H), 1.18 (m, 1H), 1.38 (m, 1H), 1.61 (m, 1H), 5.03 (s, 1H)
10	5-methyl-2-(2-methylcyclopropyl)-4,6-pyrimidinediol	MS (MH ⁺): 181
11	2-(cyclopropylmethyl)-5-methyl-4,6-pyrimidinediol	MS (MH ⁺): 181
12	2-cyclobutyl-5-methyl-4,6-pyrimidinediol	MS (M ⁺): 180
13	2-isopropyl-5-methyl-4,6-pyrimidinediol	MS (MH ⁺): 169
14	2-cyclopentyl-5-methyl-4,6-pyrimidinediol	MS (M ⁺): 194
15	[3-(2-cyclopropyl-4,6-dihydroxy-pyrimidin-5-yl)-propyl]-carbamic acid tert-butyl ester	MS (MH ⁺): 310
16	[4-(2-cyclopropyl-4,6-dihydroxy-pyrimidin-5-yl)-butyl]-carbamic acid tert-butyl ester	MS (MH ⁺): 324

3.2 Synthesis of 2-cyclopropyl-5-nitro-4,6-pyrimidinediol 17.



5

Glacial acetic acid (90 ml) is added to fuming nitric acid (40 ml) at 0 °C. The solution is warmed to 30 °C and 2-cyclopropyl-4,6-pyrimidinediol 4 (35 g, 0.25 mol) is added in portions. The temperature is kept between 30 and 40 °C. After 1h, the mixture is poured onto crushed ice and filtered. The filtrate is concentrated to 50 ml in vacuo. Methanol is added and the precipitate is filtered and dried. Pure 2-cyclopropyl-5-nitro-4,6-pyrimidinediol 17 (39.8 g, 84%) is obtained and used in the next step without further purification.


10

MS (M⁺): 197.

26

4 **EXAMPLE 4: synthesis of 4,6-dichloropyrimidine derivatives of formula IV.**

4.1 **Synthesis of 4,6-dichloro-2-cyclopropyl-5-fluoropyrimidine 18:**



3 2-cyclopropyl-5-fluoro-4,6-pyrimidinediol 3 (3.51 g, 21 mmol) is suspended in phosphorus oxychloride (15 ml). A mixture of N,N-diethylamine (3.08 g, 21 mmol) and phosphorus oxychloride (15 ml) is added dropwise to the suspension at 0 °C. The resulting mixture is stirred at 110 °C for 2 h, then cooled to room temperature. The brown solution is poured onto crushed ice and extracted five times with
10 dichloromethane. The combined organic layers are washed three times with a 1 N HCl solution, dried over magnesium sulfate and concentrated in vacuo to afford 4,6-dichloro-2-cyclopropyl-5-fluoropyrimidine 18 as an orange oil (4.80 g, 100 %) which is used in the next step without further purification.

MS (M⁺): 205/207/209.

15

Compounds described in table 2 can be synthesized in an analogous way.


124
122

Table 2

19	4,6-dichloro-2-cyclopropylpyrimidine	MS (M ⁺): 189/191/193
20	4,6-dichloro-2-cyclopropyl-5-methylpyrimidine	MS (M ⁺): 202/204/206
21	4,5,6-trichloro-2-cyclopropylpyrimidine	MS (M ⁺): 222/224/226
22	4,6-dichloro-2-cyclopropyl-5-pyrimidinyl methyl ether	MS (M ⁺): 218/220/222
23	4,6-dichloro-2-cyclopropyl-5-ethylpyrimidine	¹ H NMR (250 MHz, CDCl ₃): 1.12 (m, 4H), 1.20 (t, 3H), 2.16 (m, 1H), 2.85 (q, 2H)
24	4,6-dichloro-2-(2-methylcyclopropyl)pyrimidine	eb. = 85°C/1 mmHg
25	4,6-dichloro-5-methyl-2-(2-methylcyclopropyl)pyrimidine	MS (M ⁺): 216/218/220
26	4,6-dichloro-2-(cyclopropylmethyl)-5-methylpyrimidine	MS (M ⁺): 217/219/221
27	4,6-dichloro-2-cyclobutyl-5-methylpyrimidine	MS (M ⁺): 216/218/220
28	4,6-dichloro-2-cyclopropyl-5-nitropyrimidine	MS (M ⁺): 233/235/237
29	4,6-dichloro-2-isopropyl-5-methylpyrimidine	MS (M ⁺): 204/206/208
30	4,6-dichloro-2-cyclopentyl-5-methylpyrimidine	MS (M ⁺): 230/232/234

5 EXAMPLE 5: synthesis of compounds of formula II.

5.1 Synthesis of 6-chloro-N,2-dicyclopropyl-5-fluoro-4-pyrimidinamine 31.



10 Cyclopropylamine (11.4 g, 0.200 mol) is added to 4,6-dichloro-2-cyclopropyl-5-fluoropyrimidine 18 (4.80 g, 23 mmol) and the solution is stirred at room temperature for 1 h. The mixture is diluted with diethyl ether, washed two times with a saturated sodium bicarbonate solution. The combined organic layers are dried over magnesium sulfate and concentrated in vacuo to afford 6-chloro-N,2-dicyclopropyl-5-fluoro-4-pyrimidinamine 31 as a yellow oil (4.99 g, 95 %) which is used in the next step without further purification.

MS (M⁺): 227/229.

Compounds described in table 3 can be synthesized in an analogous way.

Table 3


32	6-chloro-N,2-dicyclopropyl-4-pyrimidinamine	MS (MH ⁺): 210/212
33	6-chloro-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine	MS (MH ⁺): 223/225
34	5,6-dichloro-N,2-dicyclopropyl-4-pyrimidinamine	MS (MH ⁺): 244/246/248
35	6-chloro-N,2-dicyclopropyl-5-methoxy-4-pyrimidinamine	MS (MH ⁺): 240/242
36	6-chloro-N,2-dicyclopropyl-5-ethyl-4-pyrimidinamine	MS (MH ⁺): 238/240
37	N-[6-chloro-2-(2-trans-methylcyclopropyl)-4-pyrimidinyl]-N-cyclopropylamine (I)	MS (MH ⁺): 224/226
38	N-[6-chloro-2-(2-trans-methylcyclopropyl)-4-pyrimidinyl]-N-cyclopropylamine	MS (MH ⁺): 224/226 [α] _D ²⁵ = +87.28 (c=1, CH ₂ Cl ₂)
39	N-[6-chloro-2-(2-trans-methylcyclopropyl)-4-pyrimidinyl]-N-cyclopropylamine	MS (MH ⁺): 224/226 [α] _D ²⁵ = -83.80 (c=1, CH ₂ Cl ₂)
40	6-chloro-N-cyclopropyl-5-methyl-2-(2-trans-methylcyclopropyl)-4-pyrimidinamine	MS (MH ⁺): 238/240
41	6-chloro-N-cyclopropyl-5-methyl-2-(2-cis-methylcyclopropyl)-4-pyrimidinamine	MS (MH ⁺): 238/240
42	N-[6-chloro-2-(cyclopropylmethyl)-5-methyl-4-pyrimidinyl]-N-cyclopropylamine	MS (MH ⁺): 238/240
43	6-chloro-2-cyclobutyl-N-cyclopropyl-5-methyl-4-pyrimidinamine	MS (MH ⁺): 237/239
44	6-chloro-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine	MS (MH ⁺): 255/257
45	6-chloro-N-cyclobutyl-2-cyclopropyl-5-methyl-4-pyrimidinamine	MS (MH ⁺): 238/240
46	6-chloro-N-cyclopropyl-2-isopropyl-5-methyl-4-pyrimidinamine	MS (MH ⁺): 226/228
47	6-chloro-2-cyclopentyl-N-cyclopropyl-5-methyl-4-pyrimidinamine	MS (MH ⁺): 252/254

(I) compound 37 was resolved into its enantiomers 38 (first eluted) and 39 (second eluted) by chromatography on a chiral support (Daicel Chiralpak AD, isopropanol/n-hexane 1/99, 20 °C).

123

6 EXAMPLE 6: synthesis of 4-hydroxypyrimidines of formula XII

6.1 Synthesis of 2-cyclopropyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-ol 48.



5 Sodium (0.417 g, 18.1 mmol) is dissolved in methanol (65 ml) under a nitrogen atmosphere. Cyclopropanecarboximidamide hydrochloride (2.19 g, 18.1 mmol) is added in one portion. The mixture is stirred at room temperature for 0.25 h, then filtered upon hyfloel. The filtrate is concentrated in vacuo to 30 ml. This free base is added to a solution of sodium (0.834 g, 36.2 mmol) in methanol (130 ml) under a
10 nitrogen atmosphere, at room temperature. 2-ethoxy-4,5-dihydro-3H-pyrrole-3-carboxylic acid ethyl ester (3.4 g, 18.1 mmol) in methanol is added and the mixture is stirred at 60 °C overnight. After cooling, the solvent is evaporated and the solid obtained is dissolved in water. The pH is adjusted at 5 with a 5 N HCl solution and the white precipitate formed is filtered and dried. 2-cyclopropyl-6,7-dihydro-5H-
15 pyrrolo[2,3-d]pyrimidin-4-ol 48 (1.88 g, 59 %) is obtained as a white powder and used in the next step without further purification.

MS (MH⁺): 178.

7 EXAMPLE 7: synthesis of 4-chloropyrimidines of formula X.

20 7.1 Synthesis of 4-chloro-2-cyclopropyl-5,6,7,8-tetrahydro-5H-pyrido[2,3-d]pyrimidine 50.



25 [3-(2-cyclopropyl-4,6-dihydroxy-pyrimidin-5-yl)-propyl]-carbamic acid tert-butyl ester 15 (1.4 g, 4.5 mmol) is suspended in phosphorus oxychloride (10 ml). A mixture of N,N-diethylaniline (0.744 g, 5 mmol) and phosphorus oxychloride (10 ml) is added dropwise to the suspension at room temperature. The resulting mixture is stirred at 100 °C overnight. The solution is poured onto crushed ice and extracted two times with dichloromethane. The aqueous layer is alkalized using a saturated
30 sodium hydrogenocarbonate solution (pH 8), extracted two times with dichloromethane, reacidified using HCl, 5N (pH 3) and extracted again with

30


dichloromethane. The combined aqueous layers are alkalised (pH 10) and the white precipitate formed is filtered and dried. The combined organic layers are dried over magnesium sulfate and concentrated in vacuo to afford a mixture of 4-chloro-2-cyclopropyl-5,6,7,8-tetrahydro-5H-pyrido[2,3-d]pyrimidine 50 and non-cyclized 3-(4,6-dichloro-2-cyclopropyl-pyrimidin-5-yl)propylamine 49. This mixture is dissolved in 1-methoxy-2-propanol and heated at 140 °C for 5 h. After cooling, the solution is diluted with dichloromethane and washed with water (2x) and with an hydrochloric acid solution (1 N). The combined organic layers are dried over magnesium sulfate and concentrated in vacuo. The resulting crude mixture is purified by chromatography on silica gel preparative plates (dichloromethane/ethanol/ammonia 97/3/0.3) to afford a solid, which is combined with the first-formed precipitate. Pure 4-chloro-2-cyclopropyl-5,6,7,8-tetrahydro-5H-pyrido[2,3-d]pyrimidine 50 is obtained as an orange solid (209 mg, 20 %).

MS (MH⁺): 210/212.

4-chloro-2-cyclopropyl-6,7,8-tetrahydro-5H-pyrimido[4,5-b]azepine 51 can be synthesized in an analogous way.

MS (MH⁺): 224/226

7.2 Synthesis of 4-chloro-2-cyclopropyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine 52.



2-cyclopropyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-ol 48 (0.5 g, 2.8 mmol) is suspended in phosphorus oxychloride (0.7 ml). A mixture of N,N-diethylaniline (0.46 g, 3.1 mmol) and phosphorus oxychloride (0.7 ml) is added dropwise to the suspension at room temperature. The resulting mixture is stirred at 120 °C for 3 h. The solution is poured onto crushed ice and extracted two times with dichloromethane. The aqueous layer is alkalised (pH 10) and extracted four times with dichloromethane. The combined organic layers are dried over magnesium sulfate and concentrated in vacuo. The crude mixture (370 mg, 68 %, 91 % purity) is used in the next step without further purification due to the instability of the compound.


MS (MH⁺): 196/198

126
124

31


8 EXAMPLE 8: synthesis of compounds of formula I.

8.1 Synthesis of N,2-dicyclopropyl-5-fluoro-6-(4-thiomorpholinyl)-4-pyrimidinamine 120.




A mixture of thiomorpholine (2.27 g, 22 mmol) and 6-chloro-N,2-dicyclopropyl-5-fluoro-4-pyrimidinamine 31 (1 g, 4.4 mmol) is stirred at 110 °C for 18 hours. After cooling, the brown solution is diluted with dichloromethane, washed two times with a saturated sodium bicarbonate solution. The combined organic layers are dried over magnesium sulfate and concentrated under high vacuum to afford a brown oil. The crude oil is purified by column chromatography (hexane/ethyl acetate: 80/20) to give N,2-dicyclopropyl-5-fluoro-6-(4-thiomorpholinyl)-4-pyrimidinamine 120 (915 mg, 71 %) as a yellowish solid.

8.2 Synthesis of N⁴-cyclohexyl-N⁶,2-dicyclopropyl-5-methyl-4,6-pyrimidinediamine 141.



A mixture of cyclohexylamine (3.78 g, 18 mmol) and 6-chloro-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine 33 (9.70 g, 3 mmol) in 1-methoxy-2-propanol (2 ml) is stirred at 125 °C for 120 hours. After cooling, the brown solution is diluted with dichloromethane, washed two times with a saturated sodium bicarbonate solution. The combined organic layers are dried over magnesium sulfate and concentrated under high vacuum to afford a brown oil. The crude oil is purified by column chromatography (dichloromethane/methanol: 97.3/2.7) to give pure N⁴-cyclohexyl-N⁶,2-dicyclopropyl-5-methyl-4,6-pyrimidinediamine 141 (0.150 g, 17 %).

8.3 Synthesis of 6-(1-azepanyl)-N⁴,2-dicyclopropyl-4,5-pyrimidinediamine 63.




6-(1-azepanyl)-N,2-dicyclopropyl-5-nitro-4-pyrimidinamine 158 was synthesized as described in 6.1. using 6-chloro-N,2-dicyclopropyl-5-nitro-4-pyrimidinamine 44 and azepane as starting material.

MS (MH⁺): 318.

To a suspension of 6-(1-azepanyl)-N,2-dicyclopropyl-5-nitro-4-pyrimidinamine 158 (0.5 g, 16 mmol) in 1,4-dioxane (35 ml) and water (35 ml) is added sodium hydrosulfite (2.19 g, 13 mmol) and ammonia (25 % solution, 1.2 ml). The mixture is stirred at room temperature for 10 h then diluted with ethyl acetate and washed three times with water. The combined organic layers are dried over magnesium sulfate and concentrated in vacuo to afford a yellow oil. The crude oil is purified by column chromatography (dichloromethane/ethanol/ammonia: 95/5/0.5) to give pure 6-(1-azepanyl)-N⁴,2-dicyclopropyl-4,5-pyrimidinediamine 63 (137 mg, 30 %) as a reddish solid.

8.4 Synthesis of 1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-piperidinone hydrate 107.




A solution of 1 N HCl (15 ml) is added to a solution of N,2-dicyclopropyl-6-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-5-methyl-4-pyrimidinamine 149 (285 mg, 0.86 mmol) in tetrahydrofuran (15 ml). The mixture is stirred at room temperature for 18 h, then diluted with dichloromethane and washed three times with sodium bicarbonate. The combined organic layers are dried over magnesium sulfate and concentrated in vacuo to afford a white paste. The compound is dried under vacuum to give pure 1-[2-

2/127
125


cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl-4-piperidinone hydrate 107 (160 mg, 61 %) as a white paste.

8.5 Synthesis of 6-azepan-1-yl-5-bromo-N,2-dicyclopropylpyrimidin-4-amine 61.



N-Bromosuccinimide (0.39 g, 2.32 mmol) is added to a solution of 6-(1-cyclopropyl)-N,2-dicyclopropyl-4-pyrimidinamine 62 (0.5 g, 1.84 mmol) in chloroform (2 ml). The mixture is stirred at 60 °C overnight then cooled, diluted with dichloromethane and washed two times with water. The combined organic layers are dried over magnesium sulfate and concentrated in vacuo. The crude mixture is purified by column chromatography (dichloromethane/ethanol: 97/3) to give pure 6-azepan-1-yl-5-bromo-N,2-dicyclopropylpyrimidin-4-amine 61 (134 mg, 21 %) as a brownish paste.

8.6 Synthesis of 4-azepan-1-yl-2-cyclopropyl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidine 155.



A mixture of azepane (18.2 ml, 142 mmol) and 4-chloro-2-cyclopropyl-5,6,7,8-tetrahydro-5H-pyrido[2,3-d]pyrimidine 59 (0.851 g, 4.06 mmol) is stirred four days at 110 °C. After cooling, the brown solution is diluted with dichloromethane and washed two times with water. The combined organic layers are dried over magnesium sulfate and concentrated under high vacuum to afford a brown oil. The crude oil is purified by column chromatography (dichloromethane/ethanol/ammonia: 90/10/1) to give pure 4-azepan-1-yl-2-cyclopropyl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidine 155 as a brown solid.

Compounds described in table 4 can be synthesized according to one of these methods.

Table 4

	Salt and/or solvate	Configuration data			Free base IUPAC NAME	MH ⁺ (M ⁺)	DSC °C (mg)	alpha
53	1 HCl		Achiral		N,2-dicyclopropyl-6-(1,3-thiazolidin-3-yl)-4-pyrimidinamine	(262)	181.3	
54	1 HCl		achiral		N-cyclopropyl-2-isopropyl-6-(1,3-thiazolidin-3-yl)-4-pyrimidinamine	(284)	204.4	
55	1 maleate		achiral		6-(1-azepanyl)-2-cyclobutyl-N-cyclopropyl-5-methyl-4-pyrimidinamine	301		
56	1 maleate		achiral		6-(1-azepanyl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine	287		
57	3/2 fumarate		achiral		6-(1-azepanyl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine	287	149.9	
58	1 maleate		achiral		6-(1-azepanyl)-N-cyclobutyl-2-cyclopropyl-5-methyl-4-pyrimidinamine	301		
59	1 maleate		achiral		N-[6-(1-azepanyl)-5-chloro-2-cyclopropyl-4-pyrimidinyl]-N-cyclopropylamine	307	85.2	
60	1 maleate		achiral		6-(1-azepanyl)-N,2-dicyclopropyl-5-fluoro-4-pyrimidinamine	291	111.2	
61			achiral		6-azepan-1-yl-5-bromo-N,2-dicyclopropylpyrimidin-4-amine	351/353		
62			achiral		6-(1-azepanyl)-N,2-dicyclopropyl-4-pyrimidinamine	273	124.6	
63			achiral		6-(1-azepanyl)-N ⁴ ,2-dicyclopropyl-4,5-pyrimidinediamine	288	(76.9)	
64	1 maleate		achiral		6-azepan-1-yl-N-cyclopropyl-2-isopropyl-5-methylpyrimidin-4-amine	289		
65	1 maleate	A-1,2	rac	trans	6-(1-azepanyl)-N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-4-pyrimidinamine	301		
66	1 maleate	B-1,2	rac	cis	6-(1-azepanyl)-N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-4-pyrimidinamine	301		

67		B-18,28	pure	trans	6-(1-azepanyl)-N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-4-pyrimidinamine	301		-58.79
68		A-18,28	pure	trans	6-(1-azepanyl)-N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-4-pyrimidinamine	301		+57.65
69	1 maleate		achiral		6-(1-azepanyl)-N-cyclopropyl-2-(cyclopropylmethyl)-5-methyl-4-pyrimidinamine	301		
70		A-1,2	rac	trans	N-[6-(1-azepanyl)-5-chloro-2-(2-methylcyclopropyl)-4-pyrimidinyl]-N-cyclopropylamine	321		
71		A-1,2	rac	trans	6-(1-azepanyl)-N-cyclopropyl-2-(2-methylcyclopropyl)-4-pyrimidinamine	287		
72	0.2 iPrOH, 1 maleate		achiral		6-(1-azocanyl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine	301		
73		A-1,2	rac	trans	6-(1-azocanyl)-N-cyclopropyl-2-(2-methylcyclopropyl)-4-pyrimidinamine	301	-108.5	
74		3,5	mixt		N,2-dicyclopropyl-6-(3,5-dimethyl-1-piperidinyl)-5-methyl-4-pyrimidinamine	301	81.2	
75	1 maleate		achiral		N,2-dicyclopropyl-6-[4-(2-methoxyphenyl)-1-piperidinyl]-5-methyl-4-pyrimidinamine	379	123.6	
76	1 iPrOH, 1 maleate		achiral		[1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-piperidinyl](diphenyl)methanol	456	86.1	
77			achiral		N,2-dicyclopropyl-5-methyl-6-[4-(trifluoromethyl)piperidin-1-yl]pyrimidin-4-amine	341	(88.4)	
78	1 maleate		achiral		N,2-dicyclopropyl-6-[4,4-difluoro-1-piperidinyl]-5-methyl-4-pyrimidinamine	309	121.9	

27/78

EMFANGSZEIT 18. APR. 12:04

AUSDRUCKSZEIT 18. APR. 12:30

79			achiral		N,2-dicyclopropyl-6-(4,4-dimethyl-1-piperidinyl)-5-methyl-4-pyrimidinamine	301		
80	1 HCl		achiral		N,2-dicyclopropyl-6-(4,4-dimethyl-1-piperidinyl)-5-methyl-4-pyrimidinamine	301		
81			achiral		1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-piperidinecarboxamide	316	230.6	
82	1 malcate		achiral		6-(4-benzyl-1-piperidinyl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine	363	132.1	
83			achiral		1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-piperidinecarboxylic acid	317	219.6	
84			achiral		1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-phenyl-4-piperidinecarbonitrile	374	145.3	
85	1 malcate		achiral		ethyl 1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-piperidinecarboxylate	345	118.9	
86			achiral		N,2-dicyclopropyl-6-(4-ethyl-1-piperidinyl)-5-methyl-4-pyrimidinamine	301		
87	1 HCl		achiral		N,2-dicyclopropyl-6-(4-ethyl-1-piperidinyl)-5-methyl-4-pyrimidinamine	301		
88			achiral		N,2-dicyclopropyl-6-(4-ethyl-4-methyl-1-piperidinyl)-5-methyl-4-pyrimidinamine	315		
89	1 HCl		achiral		N,2-dicyclopropyl-6-(4-ethyl-4-methyl-1-piperidinyl)-5-methyl-4-pyrimidinamine	315		
90			achiral		1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-piperidinol	289	150.0	
91			achiral		1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-phenyl-4-piperidinol	365		

36

92			achiral		1-[2-cyclopropyl-6-(cyclopropylamino)-5-fluoro-4-pyrimidinyl]-4-phenyl-4-piperidinol	369		
93			achiral		(1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-piperidinyl)methanol	303	113.9	
94	1 maleate		achiral		N,2-dicyclopropyl-5-ethyl-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine	301		
95	1 maleate		achiral		N,2-dicyclopropyl-5-methyl-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine	287	97.9	
96			achiral		N,2-dicyclopropyl-5-fluoro-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine	291		
97		A-1,2	rac	trans	N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine	301	91.3	
98	1 maleate	B-1,2	rac	cis	N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine	301		
99		A-	pure	trans	N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine	301		61.65
100		B-1,2	pure	trans	N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine	301		63.51
101		A-1,2	rac	trans	N-cyclopropyl-2-(2-methylcyclopropyl)-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine	287	120.3	
102	1 HCl	A-1,2	rac	trans	N-cyclopropyl-2-(2-methylcyclopropyl)-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine	287	148.1	
103	1 maleate	A-1,2	rac	trans	N-cyclopropyl-2-(2-methylcyclopropyl)-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine	287	132.1	
104		A-1,2	pure	trans	N-cyclopropyl-2-(2-methylcyclopropyl)-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine	287		65.81

105		B- 18.28	pure	trans	N-cyclopropyl-2-(2-methylcyclopropyl)-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine	287		-70.6
106	1 HCl		achiral		N,2-dicyclopropyl-5-methyl-6-(4-methylene-1-piperidinyl)-4-pyrimidinamine	285		
107	1 H ₂ O		achiral		1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-piperidinone	305		
108			achiral		N ⁴ ,2-dicyclopropyl-N ⁶ ,5-dimethyl-N ⁶ -(2-(2-thienyl)ethyl)-4,6-pyrimidinediazine	329		
109	1 maleate		achiral		N ⁴ ,2-dicyclopropyl-5-methyl-N ⁶ -(2-(2-thienyl)ethyl)-4,6-pyrimidinediazine	315	129.1	
110	1 maleate		achiral		N ⁴ ,2-dicyclopropyl-N ⁶ -(2-furylmethyl)-N ⁶ ,5-dimethyl-4,6-pyrimidinediazine	299		
111	1 maleate		achiral		N ⁴ ,2-dicyclopropyl-5-methyl-N ⁶ -(2-thienylmethyl)-4,6-pyrimidinediazine	301	151.8	
112	1 maleate		achiral		N,2-dicyclopropyl-6-(3,6-dihydro-1(2H)-pyridinyl)-5-methyl-4-pyrimidinamine	271	118.9	
113		A-1,2	rac	trans	N-cyclopropyl-6-(3,6-dihydro-1(2H)-pyridinyl)-2-(2-methylcyclopropyl)-4-pyrimidinamine	271	107.4	
114	1 HCl	A-1,2	rac	trans	N-cyclopropyl-6-(3,6-dihydro-1(2H)-pyridinyl)-2-(2-methylcyclopropyl)-4-pyrimidinamine	271		
115	1 maleate		achiral		6-(3-azabicyclo[3.2.1]oct-3-yl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine	299		

EMFANGSZEIT 18. APR. 12:04

AUSDRUCKSZEIT 18. APR. 12:30

116	1 maleate		achiral		N ⁴ ,2-dicyclopropyl-5-methyl-N ⁶ -(4-pyridinylmethyl)-4,6-pyrimidinediamine	296	165.3	
117	2 maleate	A-1,2	rac	trans	N ⁴ -cyclopropyl-2-(2-methylcyclopropyl)-N ⁶ -(4-pyridinylmethyl)-4,6-pyrimidinediamine	296		
118	1 maleate		achiral		N,2-dicyclopropyl-5-ethyl-6-(4-thiomorpholinyl)-4-pyrimidinamine (1:1)	305	89.5	
119	1 HCl		achiral		N,2-dicyclopropyl-5-methyl-6-(4-thiomorpholinyl)-4-pyrimidinamine	(290)	224.4	
120			achiral		N,2-dicyclopropyl-5-fluoro-6-(4-thiomorpholinyl)-4-pyrimidinamine	295	(87)	
121			achiral		N,2-dicyclopropyl-6-(4-thiomorpholinyl)-4-pyrimidinamine	(276)		
122			achiral		N,2-dicyclopropyl-5-methoxy-6-(4-thiomorpholinyl)-4-pyrimidinamine	307		
123	1 maleate		achiral		N-cyclopropyl-2-isopropyl-5-methyl-6-(4-thiomorpholinyl)-4-pyrimidinamine	283	89.64	
124	1 HCl	A-18,28	pure	trans	N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-6-(4-thiomorpholinyl)-4-pyrimidinamine	(304)		+48.7
125	1 HCl	B-18,28	pure	trans	N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-6-(4-thiomorpholinyl)-4-pyrimidinamine	(304)		-52.
126	1 HCl	A-18,28	pure	trans	N-cyclopropyl-2-(2-methylcyclopropyl)-6-(4-thiomorpholinyl)-4-pyrimidinamine	(290)		+68.9
127	1 HCl	B-18,28	pure	trans	N-cyclopropyl-2-(2-methylcyclopropyl)-6-(4-thiomorpholinyl)-4-pyrimidinamine	(290)		-68.6
128	1 maleate		achiral		N ⁴ -benzyl-N ⁶ ,2-dicyclopropyl-5-methyl-4,6-pyrimidinediamine	295		
129	1 maleate		achiral		N ⁴ -benzyl-N ⁶ ,2-dicyclopropyl-N ⁴ ,5-dimethyl-4,6-pyrimidinediamine	309	74.5	

27
138

130	1 HBr	A-1,2	rac	trans	N ⁴ -benzyl-N ⁶ -cyclopropyl-2-(2-methylcyclopropyl)-4,6-pyrimidinediamine	(294)		
131	1 maleate		achiral		N ⁴ ,2-dicyclopropyl-5-methyl-N ⁶ -[2-(methylsulfonyl)benzyl]-4,6-pyrimidinediamine	341	132.7	
132	1 maleate		achiral		N ⁴ ,2-dicyclopropyl-N ⁶ -(2,6-difluorobenzyl)-5-methyl-4,6-pyrimidinediamine	331	162.7	
133	1 maleate		achiral		N ⁴ ,2-dicyclopropyl-N ⁶ -(2-fluorobenzyl)-5-methyl-4,6-pyrimidinediamine	313	141.9	
134	1 HCl	A-1,2	rac	trans	N ⁴ -cyclopropyl-N ⁶ -methyl-2-(2-methylcyclopropyl)-N ⁸ -(2-nitrobenzyl)-4,6-pyrimidinediamine	354		
135	1 maleate		achiral		N ⁴ -(3,5-bis(trifluoromethyl)benzyl)-N ⁶ ,2-dicyclopropyl-5-methyl-4,6-pyrimidinediamine	431	170.8	
136	1 maleate		achiral		N ⁴ ,2-dicyclopropyl-N ⁶ -(3,5-difluorobenzyl)-5-methyl-4,6-pyrimidinediamine	331	184.9	
137	1 maleate		achiral		N ⁴ -cycloheptyl-N ⁶ ,2-dicyclopropyl-5-methyl-4,6-pyrimidinediamine	301	136.1	
138	1 maleate	A-1,2	rac	trans	N ⁴ -cycloheptyl-N ⁶ -cyclopropyl-2-(2-methylcyclopropyl)-4,6-pyrimidinediamine	301		
139	1 maleate		achiral		N ⁴ -cyclohexyl-N ⁶ ,2-dicyclopropyl-N ⁴ ,5-dimethyl-4,6-pyrimidinediamine	301	(136-137)	
140	1 maleate		achiral		5-chloro-N ⁴ -cyclohexyl-N ⁶ ,2-dicyclopropyl-4,6-pyrimidinediamine	307/309	82.9	
141	1 maleate		achiral		N ⁴ -cyclohexyl-N ⁶ ,2-dicyclopropyl-5-methyl-4,6-pyrimidinediamine	287	159.7	

40

142	1 maleate	A-1,2	rac	trans	N ⁴ -cyclohexyl-N ⁶ -cyclopropyl-2-(2-methylcyclopropyl)-4,6-pyrimidinediamine	287	174.3	
143		A-18,28	pure	trans	N ⁴ -cyclohexyl-N ⁶ -cyclopropyl-2-(2-methylcyclopropyl)pyrimidine-4,6-diamine	287		85.25
144		B-18,28	pure	trans	N ⁴ -cyclohexyl-N ⁶ -cyclopropyl-2-(2-methylcyclopropyl)pyrimidine-4,6-diamine	287		-54.4
145	1 maleate		mixt	cis & trans	N ⁴ ,2-dicyclopropyl-5-methyl-N ⁶ -(4-methylcyclohexyl)-4,6-pyrimidinediamine	301	166.0	
146		A	pure	cis or trans	N ⁴ ,2-dicyclopropyl-5-methyl-N ⁶ -(4-methylcyclohexyl)-4,6-pyrimidinediamine	301		
147			achiral		1-[2-cyclopropyl-6-(cyclopropylamino)-5-methylpyrimidin-4-yl]azepan-2-one	301		
148	1 maleate		achiral		N,2-dicyclopropyl-6-(3,4-dihydro-2(1H)-isoquinolinyl)-5-methyl-4-pyrimidinamine	321	186.0	
149			achiral		N,2-dicyclopropyl-6-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-5-methyl-4-pyrimidinamine	331	111.0	
150	1 maleate		achiral		N ⁴ ,2-dicyclopropyl-N ⁶ -(2,2-diphenylethyl)-5-methyl-4,6-pyrimidinediamine	385	157.4	
151	1 maleate	1,5	mixt		N,2-dicyclopropyl-5-methyl-6-(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-8-yl)-4-pyrimidinamine	341		
152	1 maleate	A-4a,8a	rac	trans	N,2-dicyclopropyl-5-methyl-6-octahydro-2(1H)-isoquinoliny-4-pyrimidinamine	327		

30/3

153	1 HCl		achiral		N-[6-(8-azaspiro[4.5]dec-8-yl)-2-cyclopropyl-5-methyl-4-pyrimidinyl]-N-cyclopropylamine	327		
154	1 malate		achiral		6-(1-azepanyl)-2-cyclopentyl-N-cyclopropyl-5-methyl-4-pyrimidinamine	315		
155			achiral		4-azepan-1-yl-2-cyclopropyl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidine	273		
156			achiral		4-azepan-1-yl-2-cyclopropyl-6,7,8,9-tetrahydro-pyrimido[4,5-b]azepine	287		
157			achiral		4-azepan-1-yl-2-cyclopropyl-6,7-dihydro-pyrrolo[2,3-d]pyrimidine			

Compound 97 was resolved into its enantiomers by chromatography on a chiral support (Chiralpak AD Daicel, isopropanol/isohexane/diethylamine 5/95/0.1 (v/v), 30 °C) to give compound 99 (first eluted) and compound 100 (second eluted).

Compound 95 was resolved into its enantiomers by chromatography on a chiral support (Chiralpak AD Daicel, isopropanol/isohexane/diethylamine 5/95/0.1, 30 °C) to give compound 97 (second eluted) and compound 98 (first eluted).

Compound 143 was resolved into its enantiomers by chromatography on a chiral support (Chiralpak AD Daicel, isopropanol/isohexane/diethylamine 5/97/0.1, 30 °C) to give compound 143 (first eluted) and compound 144 (second eluted).

Compound 101 was resolved into its enantiomers by chromatography on a chiral support (Chiralpak AD Daicel, isopropanol/isohexane/diethylamine 5/98/0.1, 30 °C) to give compound 101 (first eluted) and compound 102 (second eluted).

130 x 32
X**EXAMPLE 9: affinity for human muscarinic receptors.**

Chinese Hamster Ovarian cells (CHO) expressing the human recombinant m1, m2, m3, m4 and m5 receptors were cultured in Ham's F12 media supplemented with 100 IU/ml of penicillin, 100 µg/ml of streptomycin, 400 µg/ml of geneticin and 5 % of fetal bovine serum. Cell cultures were maintained in a humidified incubator at 37 °C and 5 % CO₂.

Confluent CHO cells expressing human m1, m2, m3, m4 and m5 muscarinic receptors were harvested and resuspended in phosphate buffered saline without calcium and magnesium. The cell suspension was centrifuged at 1500 x g for 3 min (4 °C). The cell pellet was homogenized in a 15 mM Tris-HCl (pH 7.5) buffer containing 2 mM MgCl₂, 0.3 mM EDTA and 1 mM EGTA. The crude membrane fraction was collected by two consecutive centrifugation steps at 40,000 x g for 25 min (4 °C). The final pellet was resuspended, at a protein concentration ranging from 2 to 6 mg/ml, in a 7.5 mM Tris-HCl (pH 7.5) buffer containing 12.5 mM MgCl₂, 0.3 mM EDTA, 1 mM EGTA and 250 mM sucrose and stored in liquid nitrogen.

Binding assays were performed according to procedure described in: Buckley N.J., Bonner T.L., Buckley C.M., Brian M.R., Mol. Pharmacol. (1989), 35, 469-476, but with slight modifications.

Briefly, 25 to 50 µg of membrane proteins were incubated at room temperature in 1 ml of a 50 mM Tris-HCl (pH 7.4) buffer containing 2 mM of MgCl₂, 0.1 nM of [³H]-NMS (N-methylscopolamine, 85 GBq/mmol, from Amersham Pharmacia Biotech, UK) and increasing concentrations of test compound dissolved in DMSO (1 % final concentration). Non specific binding was measured in the presence of 1 µM atropine. After 60 (m2) or 120 (m3) min. incubation, assays were stopped by rapid vacuum filtration of the samples through glass fiber filters (Filtermat A, Wallac, Belgium) presoaked in 0.3 % polyethylenimine for at least 2 h. Samples were further rinsed with 8 ml of ice-cold 50 mM Tris-HCl (pH 7.4) buffer. Radioactivity trapped onto the filter was counted in a Betaplate counter (Wallac). Competition binding curves were analyzed by non-linear regression with XLfit software (IDBS, UK).

EXAMPLE 10: PDE IV enzymatic activity.**Enzyme source:**

Cytosolic fraction from U937 cells pre-stimulated for 4 h at 37 °C with a mixture of rolipram 30 µM and salbutamol 1 µM (Torphy T.J., Zhou H.L., Cieslinski L.B., J. Pharmacol. Exp. Ther. (1992), 263 (3), 195-205).

SPA Phosphodiesterase assay (Amersham Pharmacia Biotech; Belgium):

Assays were performed in 100 μ L of 50 mM Tris HCl buffer (pH 7.4) containing 5 mM $MgCl_2$, 2 mM EGTA, 20 mM of [^3H]-5-AMP (40-60 Ci/mmol), the cytosolic fraction of 50,000 U937 cells and the appropriate concentration of test compound (usually 10 μ M) dissolved in DMSO (final assay concentration not exceeding 1 %). After 30 min incubation at room temperature, 0.5 mg of SPA yttrium silicate beads are added to each sample. Radioactivity bound to the beads (5'-AMP) is determined by liquid scintillation. Non PDE IV activity and/or non specific binding of the labeled substrate to the SPA beads is defined as the residual radioactivity remaining in the presence of rolipram 32 μ M (non PDE IV activity represents about 40 % of total activity). PDE IV activity is determined by subtracting the non PDE IV activity from the total activity.

Compounds according to the invention showed pIC_{50} values ranging from 6.5 to 10 for the m_3 receptor, and showed pIC_{50} values ranging from 5.7 to 8 for PDE IV. Dual high affinities were especially shown by compounds 56, 57, 59, 61, 62, 63, 64, 65, 66, 67, 72, 77, 78, 79, 80, 86, 87, 94, 95, 98, 106, 112, 113, 118, 119, 132, 144, 145, 154, 155 and 156.

EXAMPLE 11: in vitro inhibition of carbachol-induced contraction of guinea-pig trachea.

The method was developed according to the procedure described in Leff P., Dougall I.G., Harper D., Br. J. Pharmacol. (1993), 110, 239-244. Tracheal rings were prepared from male Dunkin-Hartley guinea pig. Tissues were mounted in 20 ml organ baths containing modified Krebs' solution in the presence of $3 \cdot 10^{-6}$ M indomethacin, $3 \cdot 10^{-4}$ M hexamethonium and 10^{-6} M propranolol. The bathing solution was maintained at 37 °C and gassed with 95 % O_2 -5 % CO_2 . Tissues were allowed to equilibrate for a period of 60 min under a resting tension of 1 g. Isometric contractions were measured by force-displacement transducers coupled to an IOX computer system capable of controlling automatic data acquisition and bath washout by automatic fluid circulation through electrovalves at defined times. Drugs were manually or robotically injected into the bath according to the stability of the measured signal.

At the end of the 60 min period of stabilisation, the tracheas were contracted twice with 10^{-6} M carbachol at 30 min intervals. Two cumulative concentration-response curves were successively constructed in the absence or presence of the test compound (incubation time: 1 hour). Results were obtained from at least 3 or 4 individual experiments. Control tissues were treated with the solvent.

22 131 +33

Antagonistic potency of the test compound was estimated by the calculation of pD_2 and /or pA_2 values according to the methods described by Van Rossum (Van Rossum J.M., Hurkmans J.A.T.M., Wolters C.J.J., Arch. Int. Pharmacodyn. Ther. (1963), 143, 299-330) or Arunlakshana & Schild (Arunlakshana O., Schild H.O, Br. J. Pharmacol. (1959), 14, 48-58).

Preferred compounds according to the invention show pA_2 values typically ranging from 5.5 to 8.


In the tables, the stereochemical information is contained in the three columns headed 'configuration data'. The second column indicates whether a compound has no stereogenic center (ACHIRAL), is a pure configuration isomer or enantiomer (PURE), a racemate (RAC) or is a mixture of two or more stereoisomers, possibly in unequal proportions (MIXT). The first column contains the stereochemical assignment for each recognised center, following the IUPAC numbering used in the preceding column. A number alone indicates the existence of both configurations at that center. A number followed by 'R' or 'S' indicates the known absolute configuration at that center. A number followed by '?' indicates the existence of only one but unknown absolute configuration at that center. The letter (A, B, C, D) in front is a way of distinguishing the various configuration isomers, enantiomers or racemates of the same structure. The third column precises the cis or trans isomerism.

In the tables, the melting points are in most cases determined by the onset of the DSC curve. When a visual (Kjeldomeres) melting point is given, the value is between brackets.

46

Claims:

1. A compound having the formula I, or a pharmaceutically acceptable salt thereof,



wherein

R^1 is alkyl or cycloalkyl,

R^2 is cycloalkyl,

R^3 is hydrogen, alkyl, halogen, hydroxy, alkoxy or amino,

or R^2R^3 is an alkylene bridging group,

R^4 is hydrogen or alkyl,

R^5 is cycloalkyl, arylalkyl or heterocycle-alkyl,

or NR^4R^5 is an heterocycle, which may be substituted, containing only one heteroatom which is a nitrogen atom or containing two heteroatoms wherein one is a nitrogen atom and the other is a non-oxidized sulfur atom,

with the proviso that when R^2R^3 is an alkylene bridging group, R^1 is a cycloalkyl.

2. A compound according to claim 1 wherein

R^1 is alkyl or C3-7-cycloalkyl,

R^2 is C3-7-cycloalkyl,

R^3 is hydrogen, C1-4-alkyl, halogen, hydroxy, alkoxy or amino,

or R^2R^3 is a C2-4 alkylene bridging group,

R^4 is hydrogen or alkyl,

R^5 is C3-7-cycloalkyl, arylalkyl or heterocycle-alkyl,

or NR^4R^5 is a heterocycle, which may be substituted, containing only one heteroatom which is a nitrogen atom or containing two heteroatoms wherein one is a nitrogen atom and the other is a non-oxidized sulfur atom,

with the proviso that when R^2R^3 is an alkylene bridging group, R^1 is a cycloalkyl.

132
132

47

3. A compound according to any of the preceding claims wherein R^1 is C3-4 alkyl or C3-4 cycloalkyl.
- 5 4. A compound according to claim 3 wherein R^1 is selected from the group of cyclopropyl, isopropyl, cyclobutyl, cyclopentyl, 2-methyl-cyclopropyl and cyclopropylmethyl.
- 10 5. A compound according to any of the preceding claims wherein R^2 is C3-4 cycloalkyl.
6. A compound according to claim 5 wherein R^2 is selected from cyclopropyl or cyclobutyl.
- 15 7. A compound according to any of the preceding claims wherein R^3 is hydrogen, methyl, ethyl, a Cl atom, a F atom, a Br atom, amino or methoxy.
8. A compound according to any of claims 1-4 wherein R^2R^3 is an alkylene bridging group selected from ethylene, propylene and butylene.
- 20 9. A compound according to any of the preceding claims wherein R^4 is hydrogen or C1-4 alkyl.
10. A compound according to claim 9 wherein R^4 is hydrogen or methyl.
- 25 11. A compound according to any of the preceding claims wherein R^5 is 2-(2-thienyl)ethyl, 2-furylmethyl, 2-thienylmethyl, 4-pyridinylmethyl, benzyl, 2-(methylsulfanyl)benzyl, 2,6-difluorobenzyl, 2-fluorobenzyl, 2-nitrobenzyl, 3,5-bis(trifluoromethyl)benzyl, 3,5-difluorobenzyl, cyclohexyl, cycloheptyl, 4-methylcyclohexyl, or 2,2-diphenylethyl.
- 30 12. A compound according to any of claims 1-8 wherein NR^4R^5 is 1,3-thiazolidin-3-yl, 1-azepanyl, 1-azocanyl, 3,5-dimethyl-1-piperidinyl, 4-(2-methoxyphenyl)-1-piperidinyl, 4-(hydroxy(diphenyl)methyl)-1-piperidinyl, 4-(trifluoromethyl)-1-piperidinyl, 4,4-difluoro-1-piperidinyl, 4,4-dimethyl-1-piperidinyl, 4-amido-1-piperidinyl, 4-benzyl-1-piperidinyl, 4-carboxy-1-piperidinyl, 4-cyano-4-phenyl-1-piperidinyl, 4-ethoxycarbonyl-1-piperidinyl, 4-ethyl-1-piperidinyl, 4-ethyl-4-
- 35

EMPfangszeit 18. APR. 12:04

Ausdruckszeit 18. APR. 12:29


- 5 methyl-1-piperidinyl, 4-hydroxy-1-piperidinyl, 4-hydroxy-4-phenyl-1-piperidinyl, 4-hydroxymethyl-1-piperidinyl, 4-methyl-1-piperidinyl, 4-methylene-1-piperidinyl, 4-one-1-piperidinyl, 3,6-dihydro-1(2H)-pyridinyl, 3-azabicyclo[3.2.1]oct-3-yl, 4-pyridinylmethyl, 4-thiomorpholinyl, 2-one-1-azepanyl, 3,4-dihydro-2(1H)-isoquinolinyl, 1,4-dioxo-8-azaspiro[4.5]dec-8-yl, 1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl, octahydro-2(1H)-isoquinolinyl or 8-azaspiro[4.5]dec-8-yl.
- 10 13. A compound selected from 6-(1-azepanyl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine; N-[6-(1-azepanyl)-5-chloro-2-cyclopropyl-4-pyrimidinyl]-N-cyclopropylamine; 6-azepan-1-yl-5-bromo-N,2-dicyclopropylpyrimidin-4-amine; 6-(1-azepanyl)-N,2-dicyclopropyl-4-pyrimidinamine; 6-(1-azepanyl)-N⁴,2-dicyclopropyl-4,5-pyrimidinediamine; 6-azepan-1-yl-N-cyclopropyl-2-isopropyl-5-methylpyrimidin-4-amine; 6-(1-azepanyl)-N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-4-pyrimidinamine; 6-(1-azocanyl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-[4-(trifluoromethyl)piperidin-1-yl]pyrimidin-4-amine; N,2-dicyclopropyl-6-(4,4-difluoro-1-piperidinyl)-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-6-(4,4-dimethyl-1-piperidinyl)-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-6-(4-ethyl-1-piperidinyl)-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-5-ethyl-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine; N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-(4-methylene-1-piperidinyl)-4-pyrimidinamine; N,2-dicyclopropyl-6-(3,6-dihydro-1(2H)-pyridinyl)-5-methyl-4-pyrimidinamine; 6-(3-azabicyclo[3.2.1]oct-3-yl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-5-ethyl-6-(4-thiomorpholinyl)-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-(4-thiomorpholinyl)-4-pyrimidinamine; N⁴,2-dicyclopropyl-N⁶-(2,6-difluorobenzyl)-5-methyl-4,6-pyrimidinediamine; N⁴,2-cyclohexyl-N⁶-cyclopropyl-2-(2-methylcyclopropyl)pyrimidine-4,6-diamine; N⁴,2-dicyclopropyl-5-methyl-N⁶-(4-methylcyclohexyl)-4,6-pyrimidinediamine; 6-(1-azepanyl)-N-cyclopentyl-2-cyclopropyl-5-methyl-4-pyrimidinamine; 4-azepan-1-yl-2-cyclopropyl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidine and 4-azepan-1-yl-2-cyclopropyl-5,6,7,8-tetrahydro-pyrido[4,5-b]azepine, or
- 35 pharmaceutically acceptable salts thereof.

133

14. A compound selected from 6-(1-azepanyl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine; N-[6-(1-azepanyl)-5-chloro-2-cyclopropyl-4-pyrimidinyl]-N-cyclopropylamine; 6-azepan-1-yl-2-bromo-N,2-dicyclopropylpyrimidin-4-amine; 6-(1-azepanyl)-N⁴,2-dicyclopropyl-4,5-pyrimidinediamine; 6-azepan-1-yl-N-cyclopropyl-2-isopropyl-5-methylpyrimidin-4-amine; 6-(1-azepanyl)-N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-4-pyrimidinamine; 6-(1-azocanyl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-[4-(trifluoromethyl)piperidin-1-yl]pyrimidin-4-amine; N,2-dicyclopropyl-6-(4,4-difluoro-1-piperidinyl)-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-6-(4,4-dimethyl-1-piperidinyl)-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-6-(4-ethyl-1-piperidinyl)-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-5-ethyl-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine; N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-(4-methylene-1-piperidinyl)-4-pyrimidinamine; N,2-dicyclopropyl-6-(3,4-dihydro-1(2H)-pyridinyl)-5-methyl-4-pyrimidinamine; 6-(3-azabicyclo[3.2.1]oct-3-yl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-5-ethyl-6-(4-thiomorpholinyl)-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-(4-thiomorpholinyl)-4-pyrimidinamine; N⁴,2-dicyclopropyl-N⁶-(2,6-difluorobenzyl)-5-methyl-4,6-pyrimidinediamine; N⁴,2-dicyclopropyl-5-methyl-N⁶-(4-methylcyclohexyl)-4,6-pyrimidinediamine; 6-(1-azepanyl)-N-cyclopentyl-2-cyclopropyl-5-methyl-4-pyrimidinamine; 4-azepan-1-yl-2-cyclopropyl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidine and 4-azepan-1-yl-2-cyclopropyl-6,7,8,9-tetrahydro-pyrimido[4,5-b]azepine, or pharmaceutically acceptable salts thereof.
15. A compound according to any preceding claims as a pure enantiomer.
16. A pharmaceutical composition comprising an effective amount of a compound according to any preceding claim in combination with a pharmaceutically acceptable diluent or carrier.
17. A pharmaceutical composition according to claim 16 for administration by inhalation.
18. A compound according to any of claims 1-15 or a pharmaceutically acceptable salt thereof for use as a medicament.

19. The use of a compound according to any of claims 1-15 for the manufacture of a medicament for the treatment of respiratory disorders in connection with Chronic Obstructive Pulmonary Disease or for treatment of symptoms related to chronic bronchitis, emphysema, cough, cystic fibrosis, pulmonary fibrosis, adult respiratory distress syndrome, laryngitis or asthma.
20. A method for treating respiratory disorders in connection with Chronic Obstructive Pulmonary Disease or for treating symptoms related to chronic bronchitis, emphysema, cough, cystic fibrosis, pulmonary fibrosis, adult respiratory distress syndrome, laryngitis or asthma comprising administering at least one compound according to claims 1-15 or a pharmaceutically acceptable salt thereof to a patient.

21. A compound of formula II, or a pharmaceutically acceptable salt thereof,



wherein

R¹ is alkyl or cycloalkyl

R² is cycloalkyl; and


R³ is hydrogen, alkyl, halogen, alkoxy or hydroxy.

22. A compound of formula II selected from the group consisting of 6-chloro-N,2-dicyclopropyl-5-fluoro-4-pyrimidinamine, 6-chloro-N,2-dicyclopropyl-4-pyrimidinamine, 6-chloro-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine, 5,6-dichloro-N,2-dicyclopropyl-4-pyrimidinamine, 6-chloro-N,2-dicyclopropyl-5-methoxy-4-pyrimidinamine, 6-chloro-N,2-dicyclopropyl-5-ethyl-4-pyrimidinamine, N-[6-chloro-2-(2-trans-methylcyclopropyl)-4-pyrimidinyl]-N-cyclopropylamine and its enantiomers, 6-chloro-N-cyclopropyl-5-methyl-2-(2-trans-methylcyclopropyl)-4-pyrimidinamine, 6-chloro-N-cyclopropyl-5-methyl-2-(2-cis-methylcyclopropyl)-4-pyrimidinamine, N-[6-chloro-2-(cyclopropylmethyl)-5-methyl-4-pyrimidinyl]-N-cyclopropylamine, 6-chloro-2-cyclobutyl-N-cyclopropyl-5-methyl-4-pyrimidinamine, 6-chloro-N,2-dicyclopropyl-5-nitro-4-pyrimidinamine, 6-chloro-N-cyclobutyl-2-cyclopropyl-5-

51

methyl-4-pyrimidinamine, 6-chloro-N-cyclopropyl-2-isopropyl-5-methyl-4-pyrimidinamine and 6-chloro-2-cyclopropyl-N-cyclopropyl-5-methyl-4-pyrimidinamine.

- 23. 2-methylcyclopropanecarboxamide
- 24. A compound of formula VI, or a pharmaceutically acceptable salt thereof,



wherein

- R¹ is alkyl or cycloalkyl, and
- R³ is alkoxy.

- 25. A compound of formula VI selected from the group consisting of 2-cyclopropyl-5-fluoro-4,6-pyrimidinediol, 5-fluoro-2-cyclopropyl-4,6-pyrimidinediol, 2-cyclopropyl-5-methoxy-4,6-pyrimidinediol, 2-cyclopropyl-5-ethyl-4,6-pyrimidinediol, 2-(2-methylcyclopropyl)-4,6-pyrimidinediol, 5-methyl-2-(2-methylcyclopropyl)-4,6-pyrimidinediol, (cyclopropylmethyl)-5-methyl-4,6-pyrimidinediol, 2-cyclobutyl-5-methyl-4,6-pyrimidinediol, 2-cyclopentyl-5-methyl-4,6-pyrimidinediol, [3-(2-cyclopropyl-4,6-dihydroxy-pyrimidin-5-yl)-propyl]-carbamic acid tert-butyl ester, [3-(2-cyclopropyl-4,6-dihydroxy-pyrimidin-5-yl)-butyl]-carbamic acid tert-butyl ester.
- 26. A compound selected from the group consisting of 4,6-dichloro-2-cyclopropyl-5-fluoropyrimidine, 4,5,6-trichloro-2-cyclopropylpyrimidine, 4,6-dichloro-2-cyclopropyl-5-pyrimidinyl methyl ether, 4,6-dichloro-2-cyclopropyl-5-ethylpyrimidine, 4,6-dichloro-2-(2-methylcyclopropyl)pyrimidine, 4,6-dichloro-5-methyl-2-(2-methylcyclopropyl)pyrimidine, 4,6-dichloro-2-(cyclopropylmethyl)-5-methylpyrimidine, 4,6-dichloro-2-cyclobutyl-5-methylpyrimidine, 4,6-dichloro-2-isopropyl-5-methylpyrimidine and 4,6-dichloro-2-cyclopentyl-5-methylpyrimidine.
- 27. 6-(1-azepanyl)-N,2-dicyclopropyl-5-nitro-4-pyrimidinamine.

52

28. A compound of formula X, or a pharmaceutically acceptable salt thereof,




wherein

n is 1-6, and

R¹ is cycloalkyl.

29. A compound of formula X selected from the group consisting of 4-chloro-2-cyclopropyl-6,7-dihydro-5H-pyrimido[2,3-d]pyrimidine, 4-chloro-2-cyclopropyl-5,6,7,8-tetrahydro-5H-pyrimido[2,3-d]pyrimidine, 4-chloro-2-cyclopropyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b]azepine.

30. A compound of formula XII, or a pharmaceutically acceptable salt thereof,



wherein R¹ is cycloalkyl.

31. 2-cyclopropyl-6,7-dihydro-5H-pyrimido[2,3-d]pyrimidin-4-ol.

Abstract

The present invention concerns chemical compounds combining affinity and antagonism against the human m3 muscarinic receptor with activity as selective phosphodiesterase IV (PDE IV) inhibitors, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

EMPFANGSZEIT 18. APR. 12:04

AUSDRUCKSZEIT 18. APR. 12:29

135
26
137

139
136



**Oficina Europea
de Patentes**

**European
Patent Office**

**Office européen
des brevets**

Certificación

Los documentos adjuntos son copias exactas de la Solicitud de Patente Europea descrita en la siguiente página, como se radicó originalmente

Certificate

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Attestation

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Solicitud de Patente No. Patent application No. Demande de brevet n°
02008706.0

El Presidente de la Oficina Europea de Patentes:
Por autorización

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk



Oficina Europea
de Patentes

European
Patent Office

Office européen
des brevets

110
137

Solicitud No.:
Application no.: 02008706.0
Demande no:

Fecha de presentación:
Date of filing: 18.04.02
Date de dépôt:

Solicitante/Applicant(s)/Demandeur(s):

UCB S.A.
Allée de la Recherche 60
1070 Bruselas
BÉLGICA

Título de la invención /Title of the invention/Titre de l' invention:

(Si no se indica el título de la invención, véase la descripción.

If no title is shown please refer to the description.

Si aucun titre n'est indiqué se référer à la description.)

Compuestos químicos con actividad dual, procesos para su preparación y
composiciones farmacéuticas

Prioridad(es) reivindicada(s) / Priority(ies) claimed /Priorité(s)
revendiquée(s)

País/Fecha/Expediente No. /State/Date/File no./Pays/Date/Número de dépôt:

Clasificación Internacional de Patente /International Patent Classification/
Classification internationale des brevets:


C07D/

Países contratantes mencionados en la fecha de presentación /Contracting states designated at
date of filing/Etats contractants désignées lors du dépôt:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Reivindicaciones:

1. Un compuesto que tiene la fórmula I, o una sal farmacéuticamente aceptable del mismo.



en donde

R^1 es alquilo o cicloalquilo,

R^2 es cicloalquilo,

R^3 es hidrógeno, alquilo, halógeno, hidroxilo, alcoxi o amino,

o R^2R^3 es un grupo puente alquilenos,

R^4 es hidrógeno o alquilo,

R^5 es cicloalquilo, arilalquilo o heterociclo-alquilo,

o NR^4R^5 es un heterociclo, que puede sustituirse, que contiene sólo un heteroátomo el cual es un átomo de nitrógeno o que contiene dos heteroátomos en donde uno es un átomo de nitrógeno y el otro es un átomo de azufre no oxidado,

con la condición que cuando R^2R^3 es un grupo puente alquilenos, R^1 es un cicloalquilo.

2. Un compuesto de acuerdo con la reivindicación 1 en donde

R^1 es alquilo o C_{3-7} -cicloalquilo,

R^2 es C_{3-7} -cicloalquilo,

R^3 es hidrógeno, C_{1-4} -alquilo, halógeno, hidroxilo, alcoxi o amino,

o R^2R^3 es un grupo puente C_{2-4} alquilenos.

R^4 es hidrógeno o alquilo,

R^5 es C_{3-7} -cicloalquilo, arilalquilo o heterociclo-alquilo,

o NR^4R^5 es heterociclo, susceptible de sustituirse, que contiene solo un heteroátomo que es un átomo de nitrógeno o que contiene dos

heteroátomos en donde uno es un átomo de nitrógeno y el otro es un átomo de azufre no oxidado,
con la condición que cuando R^2R^3 es un grupo puente alquileo R^1 es un cicloalquilo.

3. Un compuesto de acuerdo con cualquiera de las reivindicaciones precedentes en donde R^1 es C_{3-4} alquilo o C_{3-4} cicloalquilo.
4. Un compuesto de acuerdo con la reivindicación 3 en donde R^1 se selecciona del grupo de ciclopropilo, isopropilo, ciclobutilo, ciclofentilo, 2-metil-ciclopropilo y ciclopropilmetilo.
5. Un compuesto de acuerdo con cualquiera de las reivindicaciones precedentes en donde R^2 es C_{3-4} cicloalquilo.
6. Un compuesto de acuerdo con la reivindicación 5 en donde R^2 se selecciona de ciclopropilo o ciclobutilo.
7. Un compuesto de acuerdo con cualquiera de las reivindicaciones precedentes en donde R^3 es hidrógeno, metilo, etilo, un átomo Cl, un átomo de F, un átomo de Br, amino o metoxi.
8. Un compuesto de acuerdo con cualquiera de reivindicaciones 1-4 en donde R^2R^3 es un grupo puente alquileo seleccionado de etileno, propileno y butileno.
9. Un compuesto de acuerdo con cualquiera de las reivindicaciones precedentes en donde R^4 es hidrógeno o C_{1-4} alquilo.
10. Un compuesto de acuerdo con la reivindicación 9 en donde R^4 es hidrógeno o metilo.

11. Un compuesto de acuerdo con cualquiera de las reivindicaciones precedentes en donde R^5 es 2-(2-tienil)etilo, 2-furilmetilo, 2-tienilmetilo, 4-piridinilmetilo, bencilo, 2-(metilsulfanil)bencilo, 2,6-difluorobencilo, 2-fluorobencilo, 2-nitrobencilo, 3-5-bis(trifluorometil)bencilo, 3-5-difluorobencilo, ciclohexilo, cicloheptilo, 4-metilciclohexilo, o 2,2-difeniletilo.
12. Un compuesto de acuerdo con cualquiera de las reivindicaciones 1-8 en donde NR^4R^5 es 1,3-tiazolidin-3-ilo, 1-azepanilo, 1-azocanilo, 3-5-dimetil-1-piperidinilo, 4-(2-metoxifenil)-1-piperidinilo, 4-(hidroxi(difenil)metil)-1-piperidinilo, 4-(trifluorometil)-1-piperidinilo, 4-4-difluoro-1-piperidinilo, 4,4-dimetil-1-piperidinilo, 4-amido-1-piperidinilo, 4-bencil-1-piperidinilo, 4-carboxi-1-piperidinilo, 4-ciano-4-fenil-1-piperidinilo, 4-etoxicarbonil-1-piperidinilo, 4-etil-1-piperidinilo, 4-etil-4-metil-1-piperidinilo, 4-hidroxi-1-piperidinilo, 4-hidroxi-4-fenil-1-piperidinilo, 4-hidroximetil-1-piperidinilo, 4-metil-1-piperidinilo, 4-metileno-1-piperidinilo, 4-ona-1-piperidinilo, 3,6-dihidro-1(2H)-piridinilo, 3-azabicyclo[3-2.1]oct-3-ilo, 4-piridinilmetilo, 4-tiomorfolinilo, 2-ona-1-azepanilo, 3,4-dihidro-2(1H)-isoquinolinilo, 1,4-dioxa-8-azaspiro[4.5]dec-8-ilo, 1,3,3-trimetil-6-azabicyclo[3.2.1]oct-6-ilo, octahidro-2-(1H)-isoquinolinilo o 8-azaspiro[4.5]dec-8-ilo.
13. Un compuesto seleccionado de 6-(1-azepanil-N,2-diciclopropil-5-metil-4-pirimidinamina; N-[6-(1-azepanil-5-cloro-2-ciclopropil-4-pirimidinil)-N-ciclopropilamina; 6-azepan-1-il-5-bromo-N,2-diciclopropilpirimidin-4-amina; 6-(1-azepanil)-N,2-diciclopropil-4-pirimidinamina; 6-(1-azepanil)-N⁴,2-diciclopropil-4,5-pirimidinadiamina, 6-azepan-1-il-N-ciclopropil-2-isopropil-5-metilpirimidin-4-amina; 6-(1-azepanil)-N-ciclopropil-5-metil-2-(2-metilciclopropil)-4-pirimidinamina, 6-(1-azocanil)-N, 2-diciclopropil-5-metil-4-pirimidinamina; N,2-diciclopropil-5-metil-6-

27/14/11

[4-(trifluorometil)piperidin-1-il]pirimidin-4-amina; N,2-diciclopropil-6-(4,4-difluoro-1-piperidinil)-5-metil-4-pirimidinamina; N,2-diciclopropil-6-(4,4-dimetil-1-piperidinil)-5-metil-4-pirimidinamina; N,2-diciclopropil-6-(4-etil-1-piperidinil)-5-metil-4-pirimidinamida; N,2-diciclopropil-5-etil-6-(4-metil-1-piperidinil)-4-pirimidinamida; N,2-diciclopropil-5-metil-6-(4-metil-1-piperidinil)-4-pirimidinamida; N-ciclopropil-5-metil-2-(2-metilciclopropil)-6-(4-metil-1-piperidinil)-4-pirimidinamida; N,2-diciclopropil-5-metil-6-(4-metileno-1-piperidinil)-4-pirimidinamida; N,2-diciclopropil-6-(3,6-dihidro-1-(2H)-piridinil)-5-metil-4-pirimidinamida; 6-(3-azabicyclo[3.2.1]oct-3-il)-N,2-diciclopropil-5-metil-4-pirimidinamida; N,2-diciclopropil-5-etil-6-(4-tiomorfolinil)-4-pirimidinamida; N,2-diciclopropil-5-metil-6-(4-tiomorfolinil)-4-pirimidinamida; N⁴, 2-diciclopropil-N⁶-(2,6-difluorobencil)-5-metil-4,6-pirimidinadiazina; N⁴-ciclohexil-N⁶-ciclopropil-2-(2-metilciclopropil)pirimidina-4,6-diazina; N⁴,2-diciclopropil-5-metil-N⁶-(4-metilciclohexil)-4,6-pirimidinadiazina; 6-(1-azepanil)-N-ciclofentil-2-ciclopropil-5-metil-4-pirimidinamida; 4-azepan-1-il-2-ciclopropil-5,6,7,8-tetrahidro-pirido[2,3-d]pirimidina y 4-azepan-1-il-2-ciclopropil-6,7,8,9-tetrahidro-pirimido[4,5-b]azepina, o sales farmacéuticamentes aceptables de los mismos.


14. Un compuesto seleccionado de 6-(1-azepanil)-N,2-diciclopropil-5-metil-4-pirimidinamina; N-[6-(1-azepanil)-5-cloro-2-ciclopropil-4-pirimidinil]-N-ciclopropilamina; 6-azepan-1-il-5-bromo-N,2-diciclopropilpirimidin-4-amina; 6-(1-azepanil)-N⁴,2-diciclopropil-4,5-pirimidinadiazina; 6-azepan-1-il-N-ciclopropil-2-isopropil-5-metilpirimidin-4-amina; 6-(1-azepanil)-N-ciclopropil-5-metil-2-(2-metilciclopropil)-4-pirimidinamina; 6-(1-azocanil)-N,2-diciclopropil-5-metil-4-pirimidinamina; N,2-diciclopropil-5-metil-6-[4-trifluorometil)piperidin-1-il]pirimidin-4-amina; N,2-diciclopropil-6-(4,4-difluoro-1-piperidinil)-5-metil-4-pirimidinamina; N,2-

diciclopropil-6-(4-etil-1-piperidinil)-5-metil-4-pirimidinaamina; N,2-diciclopropil-5-etil-6-(4-metil-1-piperidinil)-4-pirimidinamina; N,2-diciclopropil-5-metil-6-(4-metil-1-piperidinil)-4-pirimidinamina; N-ciclopropil-5-metil-2-(2-metilciclopropil)-6-(4-metil-1-piperidil)-4-pirimidinamina; N,2-diciclopropil-5-metil-6-(4-metileno-1-piperidinil)-4-pirimidinamina; N,2-diciclopropil-6-(3-dihidro-1(2H)-piridinil)-5-metil-4-pirimidinamina; 6-(3-azabicyclo[3.2.1]oct-3-il)-N,2-diciclopropil-5-metil-4-pirimidinamina; N,2-diciclopropil-5-etil-6-(4-tiomorfolinil)-4-pirimidinamina; N,2-diciclopropil-5-metil-6-(4-tiomorfolinil)-4-pirimidinamina; N⁴,2-diciclopropil-N⁶-2,6-difluorobencil)-5-metil-4,6-pirimidinadiazina; N⁴,2-diciclopropil-metil-N⁶-(4-metilciclohexil)-4,6-pirimidinadiazina; 6-(1-azepanil)-N-ciclopentil-2-ciclopropil-5-metil-4-pirimidinamida; 4-azepan-1-il-2-ciclopropil-5,6,7,8-tetrahidro-pirido[2,3-d]pirimidina y 4-azepan-1-il-2-ciclopropil-6,7,8,9-tetrahidro-pirimido[4,5-b]azepina, o sales farmacéuticamente aceptables de los mismos.

15. Un compuesto de acuerdo con cualquiera de las reivindicaciones precedentes como un enantiómero puro.
16. Una composición farmacéutica que comprende una cantidad efectiva de un compuesto de acuerdo con cualquier reivindicación precedente en combinación con un diluyente o portador farmacéuticamente aceptable.
17. Una composición farmacéutica de acuerdo con reivindicación 16 para administración por inhalación.
18. Un compuesto de acuerdo con cualquiera de las reivindicaciones 1-15 o una sal farmacéuticamente aceptable del mismo para uso como un medicamento.

He
143

19. El uso de un compuesto de acuerdo con cualquiera de las reivindicaciones 1-15 para la manufactura de un medicamento para el tratamiento de trastornos respiratorios en conexión con enfermedad pulmonar obstructiva crónica o para el tratamiento de síntomas relacionados con bronquitis crónica, enfisema, tos, fibrosis quística, fibrosis pulmonar, enfermedad de la membrana hialina en adultos, rinitis o asma.
20. Un método para tratar trastornos respiratorios en conexión con enfermedad pulmonar obstructiva crónica o para tratar síntomas relacionados con bronquitis crónica, enfisema, tos, fibrosis quística, fibrosis pulmonar, enfermedad de la membrana hialina en adultos, rinitis o asma que comprende administrar por lo menos un compuesto de acuerdo con las reivindicaciones 1-15 o una sal farmacéuticamente aceptable del mismo a un paciente.
21. Un compuesto de fórmula II, o una sal farmacéuticamente aceptable del mismo,



en donde

R¹ es alquilo o cicloalquilo,

R² es cicloalquilo; y

R³ es hidrógeno, alquilo, halógeno, alcoxi o hidroxí.


22. Un compuesto de fórmula II seleccionado del grupo conformado por 6-cloro-N,2-diciclopropil-5-fluoro-4-pirimidinamina; 6-cloro-N,2-diciclopropil-4-pirimidinamina, 6-cloro-N,2-dicloropropil-5-metil-4-pirimidinamina, 5,6-dicloro-N,2-diciclopropil-4-pirimidinamina, 6-cloro-N,2-diciclopropil-5-metoxi-4-pirimidinamina, 6-cloro-N,2-

144

diciclopropil-5-etil-4-pirimidinamina, N-[6-cloro-2-(2-trans-metilciclopropil)-4-pirimidinil]-N-ciclopropilamina y sus enantiómeros, 6-cloro-N-ciclopropil-5-metil-2-(2-trans-metilciclopropil)-4-pirimidinamina, 6-cloro-N-ciclopropil-5-metil-2-[2-cis-metilciclopropil)-4-pirimidinamina, N-[6-cloro-2-(ciclopropilmetil)-5-metil-4-pirimidinil]-N-ciclopropilamina, 6-cloro-2-ciclobutil-N-ciclopropil-5-metil-4-pirimidinamina, 6-cloro-N,2-diciclopropil-5-nitro-4-pirimidinamina-6-cloro-N-ciclobutil-2-ciclopropil-5-metil-4-pirimidinamina, 6-cloro-N-ciclopropil-2-isopropil-5-metil-4-pirimidinamina y 6-cloro-2-ciclopentil-N-ciclopropil-5-metil-4-pirimidinamina.

23. 2-Metilciclopropanocarboximidamida.

24. A compuesto de fórmula VI, o sal farmacéuticamente aceptable del mismo,



en donde

R¹ es alquilo o cicloalquilo, y


R³ es alcoxi.

25. A compuesto de fórmula VI seleccionado del grupo conformado por 2-ciclopropil-5-fluoro-4,6-pirimidinadiol, 5-cloro-2-ciclopropil-4,6-pirimidinadiol, 2-ciclopropil-5-metoxi-4,6-pirimidinadiol, 2-ciclopropil-5-etil-4,6-pirimidinadiol, 2(2-metilciclopropil)-4,6-pirimidinadiol, 5-metil-2-(2-metilciclopropil)-4,6-pirimidinadiol-(ciclopropilmetil)-5-metil-4,6-pirimidinadiol, 2-ciclobutil-5-metil-4,6-pirimidinadiol, 2-ciclopentil-5-metil-4,6-pirimidinadiol, ácido [3-(2-ciclopropil-4,6-dihidro-pirimidin-5-il)-propil]-carbámico *tert*-butil

27/11/77
145

éster, ácido [4-(2-ciclopropil-4,6-dihidroxi-pirimidin-5-il)-butil]-carbámico *tert*-butil éster.

26. Un compuesto seleccionado del grupo conformado por 4,6-dicloro-2-ciclopropil-5-fluoropirimidina, 4,5,6-tricloro-2-ciclopropilpirimidina, 4,6-dicloro-2-ciclopropil-5-pirimidinil metil éter, 4,6-dicloro-2-ciclopropil-5-etilpirimidina, 4,6-dicloro-2-(2-metilciclopropil)pirimidina, 4,6-dicloro-5-metil-2-(2-metilciclopropil)pirimidina, 4,6-dicloro-2-(ciclopropilmetil)-5-metilpirimidimidina, 4,6-dicloro-2-ciclobutil-5-metilpirimidina, 4,6-dicloro-2-isopropil-5-metilpirimidina y 4,6-dicloro-2-ciclopentil-5-metilpirimidina.
27. 6-(1-Azepanil)-N,2-diciclopropil-5-nitro-4-pirimidinamina.
28. Un compuesto de fórmula X, o una sal farmacéuticamente aceptable del mismo.




en donde

n es 1-6, y

R¹ es cicloalquilo.

29. Un compuesto de fórmula X seleccionado del grupo conformado por 4-cloro-2-ciclopropil-6,7-dihidro-5H-pirrol[2,3-d]-pirimidina, 4-cloro-2-ciclopropil-5,6,7,8-tetrahidro-5H-pirido[2,3-d]pirimidina, 4-cloro-2-ciclopropil-6,7,8,9-tetrahidro-5H-pirimido[4,5-b]azepina.

30. Un compuesto de fórmula XII, o sal farmacéuticamente aceptable del mismo.



en donde R¹ es cicloalquilo.

31. 2-ciclopropil-6,7-dihidro-5H-pirrol[2,3-d]pirimidin-4-ol.

Extracto

La presente invención concierne a componentes químicos que combinan afinidad y antagonismo contra el receptor muscarínico m3 humano con actividad como inhibidores de fosfodiesterasa IV (PDE IV) selectiva, procesos para prepararlos, composiciones farmacéuticas que los contienen y su uso como farmacéuticos.

Handwritten notes in the top right corner:
A large 'X' is drawn over the text.
The text '147' is written next to the 'X'.
The text 'KID' is written above the '147'.



2do. EXAMEN DE FORMA PATENTE DE INVENCION

Folio 161

Radicación no 03-31717

Concepto Técnico no 55

Clasificación Internacional de Patentes: A61K31/505

Practicado el examen de acuerdo a lo establecido en el Art. 38 de la Decisión 486 se determinó que esta solicitud de Patente de Invención:

- SI ☒ NO ☐ Contiene un resumen de la invención (Art.26-e).
- SI ☒ NO ☐ Contiene el título o nombre de la invención (Art.27-d).
- SI ☒ NO ☐ Contiene la descripción de la invención (Art.26-b).
- SI ☐ NO ☐ NO ES APLICABLE ☒ Contiene los dibujos necesarios para comprender la invención (Art.26-d)
- SI ☒ NO ☐ Contiene una o más reivindicaciones. (Art.26-c).
- SI ☐ NO ☐ NO ES APLICABLE ☒ Han sido desarrollados los productos y/o procedimientos a partir de recursos genéticos o de sus productos derivados de los que cualquiera de los Países Miembros es país de origen. (Art. 26- h).
- SI ☐ NO ☐ NO ES APLICABLE ☒ Los productos y/o procedimientos han sido obtenidos o desarrollados a partir de los conocimientos tradicionales de las comunidades indígenas, afro americanas, o locales de los países miembros, de acuerdo a lo establecido en la Decisión 391 y sus modificaciones y reglamentaciones vigentes.(Art.26-i).
- SI ☐ NO ☒ La invención se refiere a un producto relativo a un material biológico. (Art.26-j).
- SI ☒ NO ☐ NO ES APLICABLE ☐ La prioridad coincide con la materia reivindicada.
- SI ☒ NO ☐ CUMPLE LOS REQUISITOS TÉCNICOS**

OBSERVACIONES Y OTROS: SI ☐ NO ☒ ver hoja(s) anexa(s)

EXAMINADOR TÉCNICO
202061

Bogotá D. C., enero 23 de 2003.

2020
Bogotá D C

Doctor(a)
RAMIRO CASTRO DUQUE
Apoderado(a)

REFERENCIA:	Radicación N°	03-31717
	Trámite	002
	Evento	001
	Actuación	416
	Oficio N°	063
	Folios	001

Teniendo en cuenta que la solicitud de privilegio de patente que se tramita bajo el expediente indicado en la referencia, reúne los requisitos de forma establecidos en los artículos 26 y 27 de la Decisión 486, de la Comisión de la Comunidad Andina, y en las demás disposiciones vigentes sobre la materia, se envía el extracto de la solicitud a la oficina de comunicaciones para efecto de su publicación en la Gaceta de Propiedad Industrial, conforme lo establece el artículo 40 de la Decisión 486, a partir del 14 de octubre de 2004.

No obstante lo anterior, no se tendrá en cuenta la prioridad invocada ya que *la copia certificada fue presentada en forma extemporánea.*

Cúmplase
Dado en Bogotá D C,

29 ENE. 2004


ALIX CARMENZA CÉSPEDES DE VERGEL
Jefe División de Nuevas Creaciones.

202051